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I 
ABSTRACT 
Alzheimer’s disease (AD) is an age related neurodegenerative disorder characterised by 
progressive memory loss and cognitive impairment. It is one of several 
neurodegenerative disorders occurring as a result of a process of programmed cell death 
known as apoptosis. The process is set off by various stimuli in numerous pathways that 
ultimately lead to apoptosis. AD stands out as one of the leading causes of death in the 
elderly in today’s society. 
The cholinergic hypothesis of AD states that there is an extensive loss of cholinergic 
neurons in the central nervous system that contributes to cognitive impairment. 
Acetylcholinesterase inhibitors decrease the breakdown of the neurotransmitter 
acetylcholine to maintain its post synaptic levels and compensate for the loss of 
functional brain cells. Amyloid β plaque formation has been shown to be extensively 
involved in the pathogenesis of AD. The abnormal regulation of the amyloid precursor 
protein gives rise to plaques that impair neuronal homeostasis and eventually lead to 
apoptosis. The monoamine oxidase enzymes catalyse the hydrolysis of amine 
neurotransmitters such as dopamine. The process produces peroxides that cause 
oxidative stress alongside the depletion of neurotransmitters. Inhibition of monoamine 
oxidase allows for accumulation of neurotransmitters and reduces the formation of 
oxidative free radicals to confer neuroprotection. 
Recent observations have suggested that dual cholinesterarase (ChE) and monoamine 
oxidase (MAO) inhibition is likely to be more effective against AD as observed in 
ladostigil. Herein we designed a series of compounds structurally similar to ladostigil, 
possessing an indole ring, propagylamine, carbamate and urea moieties. The main 
objective was to improve the inhibitory profile of existing molecules as well as 
eliminate the stereochemistry associated with rasagline and more recently, ladostigil. 
We also sought to improve the metabolic stability of carbamate derivatives.    
The synthesis of the compounds was carried out by nucleophilic substitution of an acyl 
chloride to the indole ring followed by the substitution of propargylamine moiety at 
position 1. Eight compounds were successfully synthesised. For structural 
characterisation purposes; NMR, MS, and IR were determined. Thereafter in vitro 
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II 
assays were carried out on four enzymes (MAO-A, MAO-B, acetyl- and 
butyrylcholinesterase) to ascertain the inhibitory capacity of the compounds. Molecular 
modelling was carried out using MOE to visualise binding interactions in the enzymes. 
The results showed that the compounds occupied the active sites of the enzymes and 
had interactions with significant amino acids.  
These assay results indicate that the compounds could act as dual non-selective 
cholinesterase inhibitors to slow down the hydrolysis of acetylcholine and hence 
increase its post synaptic levels. The cholinesterase assays provided a proof of concept 
regarding the ability of the carbamoyl moiety to inhibit the cholinesterase class of 
enzymes. We have identified the urea moiety as an improvement to the carbamoyl 
portion. The presence of the propargylamine moiety did not influence ChE activity 
negatively. 
The compounds were able to inhibit both isoforms of MAO. The results agree with the 
reported potential of the propargylamine moiety against MAO. . Compounds 2B and 4B 
had good IC50 values. Comparison with ladostigil proves that some of our compounds 
may serve as lead compounds for further development. Compound 2B was particularly 
a good inhibitor of all 4 enzymes (IC50 AChE = 3.70 µM, BuChE = 2.82 µM, MAO-A 
= 4.31 µM and MAO-B = 2.62 µM). The results of a chemical stability test showed that 
2B is more stable than the carbamate linked compound 4B. Compound 2B would 
probably prove more chemically stable than ladostigil. This compound can thus be 
considered for optimisation and perhaps development as a multipotent drug molecule 
against AD. 
This study set out to demonstrate that the carbamoyl/urea substituted indole 
propargylamine derivatives have great potential in alleviating the cholinergic symptoms 
of AD. They have the potential to reduce the rate of amyloid plaque formation in the 
brain, confer neuroprotection by inhibiting the MAO catalysed breakdown of amine 
neurotransmitters and reduce the progression of AD.   
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1 
CHAPTER 1 
1. INTRODUCTION 
1.1 BACKGROUND 
Alzheimer’s disease (AD) is an age related neurodegenerative disorder characterised by 
progressive memory loss and cognitive impairment (Goedert and Spillantini, 2006). 
Only 1 in 4 of the almost 47 million cases of AD worldwide have been diagnosed. 
Although highly prevalent in Western Europe, the disease is essentially a global 
problem incurring an estimated cost of $818 billion in 2015 and expected to reach $1 
trillion in 2018 (Prince, et al., 2015). As witnessed by the statistics, AD poses a great 
burden both to healthcare professionals and the economy with foreseen exponential 
growth. 
AD is one of several neurodegenerative disorders occurring as a result of a process of 
programmed cell death known as apoptosis. The process is set off by various stimuli in 
numerous pathways that ultimately lead to apoptosis (Spencer and Schaumberg, 2000). 
Since its discovery in the early 1900s, extensive research has been carried out to 
identify and understand the complex pathophysiology of the disease. Risk factors that 
increase the likelihood of developing AD have been identified; these include age, 
genetics and family history (Prince et al., 2015). As a result disease progression varies 
widely among individuals. 
Over the years several pathways have been indicated in the pathology of the disease. 
One of the most consistent indicators of AD is a loss of the cholinergic enzymes 
acetyltransferase and acetylcholinesterase (AChE) that serve as distinct markers of 
cholinergic progression (Perry et al., 1977). This loss of neurons together with a decline 
in mental test scores led to the cholinergic hypothesis of cognitive impairment (Perry et 
al., 1978a; Perry et al., 1978b). This states that there is an extensive loss of cholinergic 
neurons in the central nervous system that contributes to impairment in the cognitive 
and memory symptoms of the affected person (Bartus, 2000). 
The amyloid hypothesis of AD has been the dominating model of pathogenesis in AD 
and significant focus has been applied on the reduction and/or
http://etd.uwc.ac.za/
  
 
 
 
2 
modulation of amyloid β (Hardy, 2006). Neurodegeneration is linked with the 
production of Aβ from the amyloid precursor protein (APP). This gives rise to Aβ 
plaques whose removal does not reverse the damage or slow the progression of 
AD(Morris and Mucke, 2006).Recent reports have suggested that Aβ is a physiological 
antioxidant whose property is modified with age (Atwood et al., 2003).  
Reactive oxygen species seem to play an important role in the pathophysiological 
cascade leading to AD (Christen, 2000). Oxygen radicals are chemically unstable and 
highly reactive compounds formed during normal cellular metabolism. Due to their 
high reactivity, they may result in cellular and tissue damage when they reach an 
imbalance with their indigenous species (Christen, 2000; Halliwell and Gutteridge, 
2007). Neurons are vulnerable to attack by free radicals for several reasons. These 
include a low glutathione content [glutathione is a natural antioxidant] (Cooper, 1997), 
the presence of polyunsaturated fatty acids in high quantities (Hazel and Williams, 
1990) and the substantial quantities of oxygen needed for brain metabolism (Smith et 
al., 2002). Free radicals produced by reactive oxygen species i.e. peroxides, superoxide, 
hydroxyl radicals and singlet oxygen accumulate over an individual’s lifetime and 
hence supports the age factor in risk of AD. The free radicals hypothesis is able to 
account for the vastly heterogeneous nature of AD and the pathophysiology of other 
neurodegenerative disorders (Christen, 2000). 
Indirect evidence implicates nitric oxide in the mechanisms underlying cell death. The 
toxicity associated with nitric oxide is due to its reactivity to form peroxynitrite, a 
highly oxidising agent that also degrades to form hydroxyl radicals (Kirkinezos and 
Morales, 2001; Poderoso et al., 1999). The consequent oxidative stress significantly 
contributes to neuronal cell death in neurodegenerative diseases. Antioxidant therapy 
prevents neuronal cell death by either inhibiting free radical formation or preventing Aβ 
toxicity (Uttara et al., 2009). 
The monoamine oxidase (MAO) enzyme catalyses the oxidative deamination of 
neurotransmitters and neuromodulators such as dopamine, noradrenaline and 5-
hydroxytryptamine as well as some exogenous bioactive monoamines (Youdim and 
Bakhle, 2006). The enzyme, occurring in two isoforms, produces peroxides that cause 
oxidative stress alongside depletion of neurotransmitters. Inhibition of MAO permits 
http://etd.uwc.ac.za/
  
 
 
 
3 
accumulation of neurotransmitters and reduces the formation of oxidative free radicals 
toconfer neuroprotection (Burke et al., 2004; Nicotra et al., 2004). 
With such a broad spectrum of causative pathways, the treatment of AD has proved 
difficult and complicated. Registered drugs offer only a palliative care by interfering 
one pathway at a time. The approved treatment options are: 
 Anti-cholinesterases or acetylcholinesterase inhibitors decrease the breakdown 
of the neurotransmitter acetylcholine to maintain its levels. They therefore boost 
cholinergic transmission in the basal forebrain and compensate for the loss of 
functional brain cells (Stahl, 2000). Medications currently approved by 
regulatory agencies to treat the cognitive manifestations of AD and improve 
quality of life are donepezil (Aricept®), rivastigmine (Exelon®) and galantamine 
(Razadyne®, Nivalin®). These drugs are reversible inhibitors of the enzyme. 
Tacrine, the first inhibitor to be approved in1993 was discontinued due to high 
incidence of side effects, including hepatotoxicity (Bond et al., 2012; Watkins et 
al., 1994). Generally the disadvantage of this class of drugs is the modest and 
temporary benefits and failure to reduce the rate of decline in cognitive or 
functional capacities over long term (Courtney et al., 2004; Giacobini, 2000). 
Regardless, reversible anti-cholinesterases have significant benefits with plenty 
of evidence to support their use (Colovic et al., 2013). 
 Memantine is a moderate-affinity, voltage dependant, uncompetitive NMDA 
receptor antagonist approved for moderate to severe dementia of the 
Alzheimer’s type. It inhibits excessive calcium influx induced by over-
excitation of the NMDA receptor. Memantine, marketed as Ebixa®, Axura®, 
Namenda® and Memor®, is associated with less serious side-effects such as 
appetite loss and nausea (Robinson and Keating, 2006). 
All of the drugs approved for AD offer a non-permanent relief option towards the 
disease, as discussed above. With time it has turned out to be reasonable to include 
multiple therapies to address the varied pathological aspects of AD. The multi-target-
directed ligand (MTDL) approach is a promising strategy that yielded ladostigil. 
Sterling, et al., 2002 and Yogev-Falach et al., 2006 managed to synthesise and evaluate 
neuroprotective bifunctional analogue with the aminoindan structure of rasagiline and 
carbamate cholinesterase inhibitory moiety of rivastigmine. Ladostigil (TV3326) [N-
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4 
propargyl-(3R) aminoindan-5yl)-ethyl-methyl-carbamate] was initially designed for AD 
in high doses but failed to meet its endpoint in a Phase 2b clinical trial in 2012. It is 
currently under investigation for mild cognitive impairment due to its neuroprotective, 
anti-oxidant and microglial activation abilities (Avraham Pharma, 2016). 
So far research has managed to produce various combinations in this category featuring 
two or more of the following properties; monoamine oxidase-, cholinesterase- and 
amyloid β inhibition, anti-inflammatory activity, metal and iron homeostasis and anti-
apoptotic activity (Samadi et al., 2012; Silva et al., 2011). 
1.2 RATIONALE 
Currently the only drugs that have shown clinically relevant improvement in AD 
symptoms are AChE inhibitors such as tacrine and rivastigmine (Weinstock, 1999). 
These therapeutic agents act by increasing cholinergic transmission. However they do 
not posses neuroprotective activity, hence the use of MAO inhibitors like rasagiline, 
selegiline & ladostigil to combat oxidative stress (Youdim, 2013; Harkins et al., 1997). 
These MAO inhibitors have been found to confer neuprotection and studies have gone 
on to prove that this is independant of enzyme inhibition. For instance the S-isomer of 
rasagiline, TVP1022, does not inhibit MAO-B and yet is neuroprotective (Youdim, 
2013). Neuroprotective ability of these molecules was found to be brought about by the 
propargylamine moiety which posseses neurorescue activity via down regulation of the 
anti-apoptotic B-cell lympoma 2 (BCL-2) family of proteins that control apoptosis. 
Furthermore propargylamine reduces the expression of APP that contributes to the 
production of amyloid plaques in the brain (Bar-Am et al., 2005). 
1.2.1 MULTI-TARGET DIRECTED LIGANDS 
Neurodegenerative disorders can be treated in one of two possible ways (Figure 1.1). 
The first approach is the use of more than one drug to treat a particular condition 
(polypharmacy). Another approach would be the combination of drugs into a single 
dosage form as opposed to taking them separately, probably as a way of improving 
patient compliance and / or targeting multiple pathways and finally, through a single 
drug that may act at more than one site/receptor/system in order to have a synergistic 
effect (Mdzinarishvili et al., 2005; Youdim, 2010).Research in medicinal chemistry is 
moving from compounds with single mechanisms to multifunctional compounds in 
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6 
This approach is evident from the development of drugs such as ladostigil, a reversible 
acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) inhibitor and an 
irreversible MAO-B inhibitor, which was derived from two known neuroactive drugs, 
namely rasagiline and rivastigmine. The design of ladostigil enables it to block the 
activity of MAOs and subsequent hydrogen peroxide generation, thus preventing the 
Fenton reaction and the formation of neurotoxic free radical species. In addition, 
MAOs’ inhibition confers potential antidepressant activity by increasing the levels of 
dopamine, noradrenaline, and serotonin in the central nervous system (Youdim and 
Buccafusco, 2005). In addition to this, ladostigil also showed APP processing 
regulation and mitochondrial membrane potential stabilisation (Bar-Am et al., 2008; 
Weinreb, 2008). Furthermore, ladostigil proved neuroprotective against oxidative 
stress-induced apoptosis (Van der Schyf et al., 2007). 
1.2.2 INDOLE POLYCYCLIC RING 
In the context of the discovery of neuroprotective agents an indole scaffold possesses 
efficiency in scavenging free radicals and as an antioxidant (Buemi et al., 2013). The 
indole polycyclic ring has been investigated in the design of potential agents for 
neurodegenerative disorders. The indole moiety was used to produce AChE-induced Aβ 
aggregation inhibitors (Figure 1.3). The indole ring (as a part of a heterodimer in which 
tacrine was attached via a suitable linker) was shown to occupy the entrance of the 
cationic gorge of the AChE enzyme and interact with Trp 286 (Cavalli, et al., 2008). 
This dual action of the compound allowed for the inhibition of major pathways that lead 
to neuronal death.  
N Z
Y NH
O
X
NH
N
R
1
R
3
R
2
 
Figure 1.3: Structure of indole based dual AChE / Aβ aggregation inhibitors (Muñoz-
Ruiz et al., 2005) 
The indole structure was also used in the design and synthesis of a series of 2,5 
disubstituted indole derivatives that showed to be selective inhibitors of human 
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7 
neuronal nitric oxide synthase (nNOS) and MAO-B. In this seriesPF9601N (Figure 
1.4) showed the best dual MAO-B and nNOS inhibition (Fernández García, et al., 
1992). Structure activity relationships of the series indicated that an aromatic 
substitution at the 5 position shifted the selectivity of the compounds towards MAO-B. 
PF9601N and its metabolite has demonstrated neuroprotective effect in models of PD. 
The synergism stemming from MAO and nNOS inhibition showed considerable 
antioxidant activity (Bellik et al., 2010). 
N
H
O
NH
CH
 
Figure 1.4: Structure of PF9601N. 
Tzvetkov et al., 2014, investigated indazole and indole carboxamides for selective and 
reversible MAO-B inhibition (figure 1.5). The most potent compound was an indole-5-
carboxamide analogue. The results suggested that the nitrogen in position 1 of the 
indole is important for MAO-B binding and compound potency.  
NH
NH Cl
Cl
O
 
Figure 1.5: Structure of N-(3,4-dichlorophenyl)-indole-5-carboxamide. [IC50hMAO – 
A: 1.30 µM, hMAO – B:  0.227 µM] (Tzvetkov et al., 2014) 
From the above examples it is clear that the indole scaffold possesses great potential in 
neurodegeneration to design compounds able to inhibit MAO, nNOS and possess anti-
apoptotic activity. 
1.2.3 CHOLINESTERASE INHIBITION 
Regulation of Ach turnover and levels in the neurons and synaptic junction plays an 
important role in neurodegenerative diseases, particularly AD. The use of AChE 
inhibitors increases the post synaptic levels of Ach by inhibiting the catalytic activity of 
the enzyme (Fifer, 2012).AChE inhibitors inhibit AChE in either of two ways; those 
that react with the enzyme to form a more stable acylated enzyme and those that bind to 
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AChE with greater affinity than Ach without reacting with the enzyme (e.g. carbachol 
an alkyl carbamate). The former include arylcarbamates, such as physostigmine and its 
analogues, which bind to the catalytic site of AChE. The carbamate is hydrolysed via 
esterificaion of the carbamoyl group to the serine residue forming a carbamylated 
enzyme. Aryl carbamates have better affinity for AChE than their alkyl counterparts 
hence they possess superior activity (Tarihi, Çokuğraş, and Adresi, 2003; Giacobini, 
2003; Fifer, 2012). The activity of this moiety (Figure 1.6) was first observed in the 
extracted alkaloid physostigmine and this led to efforts to improve AChE inhibition by 
using the carbamate scaffold in drug design efforts. 
N
R
3
R
2
O
R
1
O
 
Figure 1.6: Structure of the carbamate moiety 
1.2.4 MONOAMINE OXIDASE INHIBITION 
The MAO enzymes (A and B isoforms) natively metabolise amine neurotransmitters 
and have been identified as attractive agents for the treatment of neurological disorders 
(Youdim, Edmondson, and Tipton, 2006). Inhibitors of the enzyme are expected to 
protect form neurodegeneration due to their ability to reduce the formation of peroxides 
and radical species from amine catalysis, this independent of their inhibitory 
function.MAO inhibitors are currently registered for depression and Parkinson’s disease 
and widely investigated for AD. The propargylamine moiety of selegiline was identified 
to possess MAO inhibitory, neuroprotective and neurorescue capacity, the latter via at 
least seven accepted mechanisms (Riederer, Danielczy, and Grunblatt, 2004). 
Propargylamine derived neuroprotective compounds such as ladostigil are generally 
anti-apoptotic (Youdim, Edmondson, and Tipton, 2006). The moiety has been widely 
applied in the design of multi potent ligands for the design of potential agents effective 
against AD. 
1.3 AIM 
Recent observations have suggested that dual ChE and MAO inhibition is likely to be 
more effective against AD (Zhang, H.-Y. 2005) as indicated by ladostigil a novel dual 
ChE/MAO inhibitor that is currently in Phase 2b clinical trials for mild cognitive 
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9 
impairement. However only the R-enantiomer of ladostigil is active, raising issues of 
synthesis and in vitro stability. The carbamate bond on the compound is also open to 
acid hydrolysis and once this metabolism takes place, it leaves a non-inhibiting 
neuroprotective molecule TV3279(Avraham Pharma, 2016; Sterling, et al., 2002).This 
led us to the new series of proposed compounds (Table 1.1and Figure 1.7).  
Table 1.1:Proposed series of compounds 
1A 
N
H
NH
O
N
 
1B 
N
NH
O
N
 
2A N
H
NH
O
N
 
2B NNH
O
N
 
3A 
N
H
O
O
N
 
3B 
N
O
O
N
 
4A N
H
O
O
N
 
4B NO
O
N
 
We set out todesigna series of compounds structurally similar to ladostigil, but based on 
an indole structure, featuring the propagylamine moiety, with a carbamate or urea at the 
5 or 6position (Table 1.1).Our objectivewas to improve the inhibitory profile of 
existing inhibitors as well as eliminate the stereochemistry associated with rasagline 
and more recently, ladostigil.It was hypothesised  that these compounds will serve as 
dual AChE/BuChE and MAO-A or B inhibitors and possess superior activity and 
pharmacokinetic profiles compared to ladostigil and other anti-AD drugs (Figure 1.7). 
To achieve the above mentioned aim, the following objectives were set out to be met: 
 Design a series of compounds based on literature and currently available 
treatment options. 
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10 
 Explore the potential binding interactions for these proposed compounds at the 
MAO and cholinesterase (ChE) enzyme active sites, respectively, using 
molecular modelling software. 
 Synthesise the compounds using conventional and microwave synthetic 
techniques. 
 Perform structural elucidation by means of 1H and 13C NMR, mass and infrared 
spectroscopy on the synthesised compounds. 
 Evaluate the compounds in vitro for possible AChE, BuChE, MAO-A and 
MAO- B inhibitory activity. 
 Assess the chemical stability of the compounds. 
 
 
R
2
O
N
 
 
 
Figure 1.7: The rationale used to conjugate different functional groups to indole 
structure as well as the expected structure activity relationships (SAR) of the 
compounds 
1.4 CONCLUSION 
We expect the compounds to display the ability to act upon multiple pathways against 
AD namely acetylcholine hydrolysis, MAO activity and apoptosis. The expected 
structure activity relationships are summarised in Figure 1.7. We hypothesized that the 
compounds would possess superior activity compared to ladostigil and other known 
inhibitors of the enzymes. This study could thus identify new potential MTDLs that 
may reduce the progression of AD and relieve the burden of the disease 
  
Indole polycyclic ring could 
contribute to improved MAO 
and NOS inhibition as well as 
eliminate chirality seen in 
ladostigil. 
Propargylamine moiety:could interact 
with the FAD co-factor of the MAO 
enzyme and confer neuroprotection 
independently as well. 
The carbamate- or urea 
moiety may enhance 
AChE & BuChE 
inhibitory activity. 
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CHAPTER 2 
2. LITERATURE REVIEW 
2.1 INTRODUCTION 
Neurodegenerative disorders affect a wide number of the elderly population as well as 
the family members and caretakers of the affected patients. The discovery of improved 
treatments is of critical importance in the prevention and symptomatic relief of these 
conditions of which AD is one. This second chapter will address AD as well as various 
neuroprotective strategies in depth. 
2.2 NEURODEGENERATIVE DISORDERS 
Acute and chronic neurodegenerative diseases are illnesses of cell death associated with 
high morbidity and mortality rates with few to no effective options of treatment 
available. They are mainly characterised by neuronal cell death (Yuan and Yankner, 
2000). Neurodegenerative diseases include stroke, brain trauma, amyotrophic lateral 
sclerosis (ALS), Huntington’s disease, Parkinson’s disease and Alzheimer’s disease. 
Central nervous system (CNS) tissue has very limited degenerative capacity, if any, so 
it is of the utmost importance to limit the damage caused by neuronal death (Eriksson et 
al., 1998). Cell death occurs by either of two ways: necrosis or apoptosis.  
Necrosis is the death of cells after acute ischaemia or trauma to the brain and/ or spinal 
cord. It follows a sudden biochemical collapse, which leads to the generation of free 
radicals and excitotoxins and in turn cell death. Cell necrosis occurs in such a complex 
and rapid manner that is not easy to treat or prevent (Martin, 2001; Kerr, Wyllie and 
Currie, 1972). 
Apoptotic cell death, also known as programmed cell death, is the predominant form of 
cell death in chronic neurodegenerative disorders. During apoptosis, a biochemical 
cascade activates protease enzymes that destroy molecules that are required for cell 
survival and others that mediate a programmed cell suicide (LeBlanc, 2005). Various 
kinds of stimuli have been proposed by in vivo and in vitro experiments to induce 
apoptosis of dopaminergic neurons (Ziv, et al., 1994). 
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2.3 ALZHEIMER’S DISEASE 
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder of subtle onset, 
characterised by memory loss and cognitive impairment (Khachaturian, 1985). Dr Alois 
Alzheimer, a German psychiatrist, first observed it in a patient presenting with senile 
dementia. The patient was under observation from 1901 till 1906 upon her death 
(Ashford, Schmitt and Kumar, 1996; Stelzmann, et al., 1995). 
The symptoms of AD can be divided into four stages, with a progressive pattern of 
functional and cognitive impairment. It starts with the mild effects of ageing on 
memory such as an occasional forgetfulness of exact details and minor short term 
memory loss (Backman et al., 2004). In early stage Alzheimer’s an increasing 
impairment of cognition and memory including not remembering the episodes of 
forgetfulness is observed. At this point one may forget the names of friends and family 
and have some confusion in situations outside the familiar. These changes may only be 
noticed by those close to the patient (Black, 2012). In the moderate stage of the disease 
the subjects are not able to perform the common activities of daily living hindering their 
independence. Motor activities become less coordinated, the memory worsens and 
insomnia sets in (Frank, 1994). At this point it becomes very difficult for the patient to 
remember recently acquired information or to know where they are at a given moment. 
The late stage, which is the last and dementia stage of the disease, involves the 
complete dependence and mental incapacity of the patient (Förstl and Kurz, 1999). 
Language is reduced to simple phrases and single words, eventually leading to loss of 
speech (Frank, 1994). People with severe AD will ultimately not be able to perform any 
task on their own and will get to a point where they are bedridden and unable to feed 
themselves. Death eventually occurs due to infection or pneumonia and not the disease 
itself (Förstl and Kurz, 1999; Black, 2012). 
2.4 AETIOLOGY AND PATHOPHYSIOLOGY 
The major pathological hallmarks of AD include neurofibrillary tangles (NFTs), 
amyloid (senile or neuritic) plaques and synaptic loss (Katzman and Saitoh, 1991). The 
amyloid peptide is the principal component of the senile plaque and is a large 
contributor to AD (Selkoe, 1996). Besides the amyloid β (Aβ) plaques and the NFTs, 
the brains of AD patients exhibit evidence of reactive oxygen species and reactive 
nitrogen species (ROS and RNS, respectively) mediated injury (Praticò and Sung, 
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2004). Figure 2.1 below illustrates how these pathways correlate and ultimately lead to 
AD. 
 
Figure 2.1: Various pathways leading to AD 
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2.4.1 AMYLOID HYPOTHESIS
The amyloid hypothesis is a prevailing pathological model of AD that has recently 
gained acceptance. According to the hypothesis, the overproduction and accumulation 
of Aβ peptides in plaques represents an early 
of AD leading to the formation of neuritic or senile plaques. The cytoskeletal changes 
that arise from the hyperphosphorylation and intracellular aggregation of microtubule
associated tau protein form neurofibrillar
phenomena. Both pathological cascades impair neuronal homeostasis and eventually 
result in cell death and neurodegeneration. These changes manifest clinically with 
slowly progressive cognitive decline (evolving fro
complete dementia), behavioural symptoms and functional impairment (Hardy, 2006; 
Hardy, 2009; Morris and Mucke, 2006). Amyloid β originates from the cleavage of the 
amyloid precursor protein (APP) into smaller peptides by non
secretase and amyloiodogenic β
APP secretases, leading to the activation of the amyloiodogenic pathways, is associated 
with the overproduction of toxic amyloid species. Aβ oligomers 
neurotoxic effects (Morris and Mucke, 2006).
Figure 2.1: Abnormal pathology characteristic of Alzheimer’s disease. Illustration from 
http://www.ahaf.org/alzheimers
Neurofibrillary tangles (NF
constituted by intracellular aggregates of paired helical filaments, which arise from the 
collapse of the neuronal cytoskeleton. The structure and function of microtubules are 
impaired as a consequence of the abnormal hyperphosphorylation of the tau protein 
(Morris and Mucke, 2006). Hyperphosphorylated tau aggregates into oligomers to form 
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helical filaments which in turn form fibrillary tangles (Figure 2.2) (Meraz-Ríos et al., 
2010). 
2.4.2 CHOLINERGIC HYPOTHESIS 
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Figure 2.3: Synthesis of acetylcholine 
Choline acetyltransferase (CAT) is an enzyme that catalyses the acetylation of choline 
by acetyl coenzyme A to produce acetylcholine and coenzyme A. The original building 
blocks, acetate and choline, enter the nerve cell via specific transporters. After CAT 
intervention, the resultant acetylcholine is stored in presynaptic neuronal vesicles until 
it is released into the synapse during neurotransmission. In the synapse acetylcholine 
binds to nicotinic and muscarinic (cholinergic) receptors of the postsynaptic neuron 
resulting in a transfer between neurons (Figure 2.4). CAT is produced mainly by the 
nucleus basalis of Meynert in the basal forebrain (Hebb and Whittaker, 1958).  
Memory impairment and dementia are primary symptoms of AD and this is supported 
by Gibson and Peterson (1981) who observed that aged cholinergic neurons were 
unable to synthesize acetylcholine without potassium stimulation. This impairment 
results in a consistent reduction in CAT and thus acetylcholine levels. Excess 
acetylcholine post synapse is hydrolysed by the cholinesterase enzyme to recyclable 
choline and acetate and terminates transmission of the impulse. In the brain of an AD 
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patient; production of acetylcholine is lower than its hydrolysis resulting in idle nerve 
cells that eventually die and waste away (Francis 
Figure 2.4: The cycle of events of acetylcholine synthesis and breakdown.
Multiple human studies have indicated that forebrain cholinergic pathways to the 
thalamus serve important functional roles in conscious awareness, attention, working 
memory and other cognitive processes 
enzyme responsible for the synthesis of acetylcholine was found to be significantly 
reduced in pathological samples from the cortex and hippocampus in Alzheimer’s 
patients (Davies and Maloney, 1976; Perry 
stated the cholinergic hypothesis to be essentially a loss of cholin
CNS that contributes to the cognitive decline associated with advanced age and AD. 
The cortex and hippocampus have also exhibited a depolarisation
release and choline uptake in nerve terminals to replenish the acetylcholine (
Ball, and Colhoun, 1983; Nilsson 
cholinergic projection neurons in the nucleus basalis of Meynert, led to the conclusion
that the pathogenesis of AD was mostly represented by the degeneration of the 
cholinergic connection from the nucleus basalis of Meynert to the cortex and 
hippocampus. There exists ample evidence to conclude that assault to the forebrain 
cholinergic neurons could result in interference with acetylcholine release for normal 
brain function (Burk et al
et al., 1999). 
 
(Perry et al., 1999). The activity of CAT, the 
et al., 1977). A study by Bartus, (2000) 
ergic function in the 
-induced acetylcholine 
et al., 1986). At the same time, a reduced number of 
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2.5 CHOLINESTERASES 
Cholinesterases are widespread enzymes found in both cholinergic and non-cholinergic 
tissues as well as in plasma and other bodily fluids (Massoulié et al., 1993). They are 
classified into two forms according to their substrate specificity, behaviour in excess 
substrate and susceptibility to inhibitors (Tarihi, Çokuğraş and Adresi, 2003). 
Acetylcholinesterase (AChE) also referred to as ‘true cholinesterase’ is encoded by a 
gene on chromosome 7 (Aldridge, 1953). It is the more prominent of the cholinesterases 
and the only one consistently associated with cholinergic pathways. It was found that 
cholinergic neurons display an AChE rich enzyme activity in the perikaryon, proximal 
dendrite and axon (Mesulam and Geula, 1991). AChE is known to be abundantly 
available in the brain, muscle and erythrocyte membrane (Dave, Syal, and Katyare, 
2000).  
The second cholinesterase, found mainly in the liver, heart and lungs is called 
butyrylcholinesterase (BuChE). It is also known as pseudocholinesterase or non specific 
cholinesterase and is present in much lower concentrations than AChE with restricted 
distribution in the central nervous system (Dave, Syal, and Katyare, 2000; Mesulam, 
2000).  
The two cholinesterases present similar soluble molecular forms in tissues and body 
fluids with differing tissue distribution. These oligomeric forms are summarised as 
follows: 
1. Type I amphiphilic dimers: These are dimers anchored to plasma membranes 
by glycophosphotidyl inositol in the muscles, erythrocytes and lymphocytes. 
This is the more abundant form of AChE. 
2. Type II amphiphilic monomers and dimers: These lack a glycolipid anchor. 
They are solubilised by salt solutions and abundant in the brain, muscles and 
intestine for both cholinesterases. 
3. Hydrophobic-tailed tetramers: This form is anchored to the plasma membrane 
by a hydrophobic polypeptide subunit. Hydrophobic tailed tetramers are 
abundant in the central nervous system. 
4. Asymetric forms: This form of the enzymes is characterised by the presence of 
a collagen-like tail for support to the basal lamina. It is formed by the triple 
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helical structure of three collagenic units each associated with either one, two or 
three tetramers of cholinesterases. It is more abundant for AChE than BuChE in 
nervous muscle junctions. 
5. Soluble tetrameric form: This is composed of four identical monomers and 
stabilised by hydrophobic interactions of hydrophobic amino acids at the C 
terminal of the monomers. This form is most abundant for BuChE in body fluids 
(Tarihi, Çokuğraş, and Adresi, 2003b; (Massoulié, Sussman, et al., 1993; 
Altamirano and Lockridge, 1999). 
AChE and BuChE both have the capacity to hydrolyse acetylcholine (Ach), be it in 
different ratios.  Excess Ach levels in the brain cause saturation of AChE and in turn 
increase the activity of BuChE towards the neurotransmitter (Giacobini, 2004). In as 
much as AChE hydrolyses more Ach than BuChE, the latter contributes more to AD 
because of the decreased levels of the true cholinesterase (Mesulam et al., 2002). 
AChE and BuChE share a 65% amino acid sequence homology and have similar 
molecular forms and active site structure (Allderdice et al., 1991). Early kinetic studies 
indicate that the active site of AChE contains two subsites, the esteratic and anionic 
subsites, corresponding to the catalytic and choline binding pockets respectively. The 
anionic active subsite interacts with the charged quaternary group of the choline moiety 
of acetylcholine (Augustinsson et al., 1950; Rosenberry, 2006). It contains the amino 
acids Trp 86, Tyr 133, Tyr 337 and Phe 338 and these bind the quaternary 
trimethylammonium choline moiety of the substrate mainly through π-cation 
interactions (Harel et al., 1993) positioning the ester optimally at the acylation site. The 
acyl pocket, responsible for substrate selectivity by preventing access of the larger 
choline esters is composed of Phe 295 and Phe 297. The oxyanion hole, Gly 121, Gly 
122 and Ala 204, provides hydrogen bond donors that stabilise the tetrahedral transition 
state of the substrate (Ordentlich et al., 1998). Cationic substrates are not bound by a 
negatively charged amino acid in the anionic site, but by interaction of 14 aromatic 
residues that line the gorge leading to the active site (Colovic et al., 2013).  Among the 
aromatic amino acids, Trp 84 is reported to critical and not substitutable (Tougu, 2001). 
The esteratic subsite or CAS where Ach is hydrolysed contains a catalytic triad of three 
amino acids namely Ser 203, His 447 and Glu 334 (Figure 2.5) (Colovic et al., 2013).   
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In addition to these two subsites of the catalytic centre, AChE also possesses one or 
more additional binding sites for its substrates. This ‘peripheral’ anionic site (PAS), 
very different to the choline binding pocket of the active site, has been implicated in the 
inhibitory characteristic of acetylcholinesterase (Mooser and Sigman, 1974; Reiner et 
al., 1991).The PAS lies essentially on the surface of AChE, and it binds acetylcholine 
as the first step in the catalytic pathway (Sussman et al., 1991; Hosea et al., 1996). It is 
also responsible for modulating the catalysis as well as the binding of specific 
inhibitory compounds (Johnson and Moore, 2006). The PAS has also been identified as 
a site promoting non-cholinergic functions: cell adhesion and neurite outgrowth in 
developing and transformed neural cells and amyloiodosis through an interaction with 
the Aβ in AD (Hosea et al., 1996; Inestrosa et al., 1996; Inestrosa and Alarcón, 1998).  
a) b)  
Figure 2.5: a) Schematic representation of AChE binding sites (Colovic et al., 2013). 
b)Ribbon structure of the AChE protein in complex with fasciculin-2 (RCSB Protein 
Data Bank). 
The PAS consists of 5 residues namely Tyr 72, Asp 74, Tyr 124, Trp 286 and Tyr 341 
clustered around the entrance of the active site gorge (Harel et al., 1993). The site has 
also been shown to have interaction with a large omega loop that incorporates Tyr 72 
and Asp 74. It has been proposed that this loop may be involved in the accessibility of 
small molecules to the active site as well as allosterism (Shi et al., 2003). There are ten 
acidic residues in the area surrounding the PAS.  This concentration of negative charge, 
the ‘annular electrostatic motif’ is shared by AChE and homologous signalling 
molecules but not by BuChE (Botti et al., 1998). The aromatic PAS residues, with Trp 
286 at their core, have been shown to act synergistically due to the very large increases 
in inhibition constants induced by multiple mutants (Bourne et al., 1999). The aromatic 
rings of Tyr 72 and Tyr 124 flank the indole ring of Trp 286 and together interact with 
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charged groups of ligands (Johnson and Moore, 2006b). The indole ring of Trp 286 
exhibits a variety of interactions including aromatic-aromatic, stacking and π-cation 
(Kreienkamp et al., 1991) depending on the nature of the ligand. Significant shifting of 
the indole is also observed when comparing crystal structures of apo- and complexed 
AChE (Bourne, Taylor, and Marchot, 1995) indicating its importance in ligand binding. 
Asp 74, like Trp 286, is also able to utilise several different interaction modes, 
operating by charge-charge or hydrogen bond interactions mediated by its carboxylated 
moiety. The residues also appears to act as a trap for charged substrate (Mallender, et 
al., 2000; Hosea, et al., 1996b) 
Regarding the structure of BuChE, each monomer has a narrow 20Å deep active site 
gorge lined by approximately 55 amino acid residues. Figure 2.6 show a schematic 
representation of this active site. The PAS is found at the mouth of the gorge with Asp 
70 and Tyr 332 involved in the initial binding of positively charged substrates and in 
activation control. BuChE contains a hydrogen bond between these two residues which 
controls the functional design of the active site gorge. When a positively charged 
substrate is bound to the enzyme by a cation-π interaction with the aromatic ring of Tyr 
332, the substrate interacts with the negatively charged Asp 70 and this process triggers 
a change in the conformation of the monomer. Thereafter the two flexible arm of the 
omega loop come close to each other and the substrate moves down to the Trp 82 
residue of the choline binding site. Trp 82 also forms a cationic-π complex with the 
substrate (Masson et al., 1997; Masson et al., 1999; Masson et al., 2001).  
a) b)  
Figure 2.6a: Schematic representation of BuChE binding sites. (Tarihi, Çokuğraş, and 
Adresi, 2003b); b: Ribbon structure of the BuChE protein (RCSB Protein Data Bank). 
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The oxyanion hole, found near the choline binding site includes Gly 116, Gly 117 and 
Ala 199, helps to rotate the substrate to a position where it can be hydrolysed by Ser 
198 (Ekholm and Konschin, 1999). When the substrate rotates horizontally, the 
substrate binds to the acyl binding pocket of the enzyme active site. Leu 286 and Val 
288 are found in the acyl binding pocket of BuChE (Phe 295 and Phe 297 in AChE) and 
allow for catalysis of larger acyl group containing substrates such as butyrylcholine 
(Radic et al., 1993). Stabilised substrate is hydrolysed by the catalytic triad, composed 
of Ser 198, His 438 and Glu 325, in the esteratic site of the active centre (Masson et al., 
1997). It is important to note that six of the 14 aromatic amino acid residues lining the 
active site gorge of AChE are replaced by aliphatic residues in BuChE. This explains 
the larger volume of the BuChE active site gorge in comparison. The replacement is 
also responsible for selective sensitivity against different inhibitors of the enzymes 
(Saxena et al., 1999). 
2.6 MONOAMINE OXIDASE 
Monoamine oxidase (MAO) is an outer mitochondrial membrane bound flavin 
containing enzyme with a molecular weight of about 60 kDa, it plays an important role 
in the metabolism of endogenous and exogenous amines (Weyler, Hsu, and Breakafield, 
1990; Shih, Chen, and Ridd, 1999). Intraneuronal MAO terminates the action of 
endogenous amine neurotransmitters, regulates intraneuronal amine stores and protects 
cells from dietary amine (false transmitters) (Youdim, Edmondson, and Tipton, 2006). 
The enzyme exists in two isoforms MAO-A and MAO-B, these isoforms have different 
substrates specificities in that MAO-A catalyses the oxidation of serotonin whilst 
MAO-B catalyses the oxidation of both benzylamine and 2-phenylethylamine. Other 
neurotransmitters like dopamine, norepinephrine, epinephrine, tryptamine and tyramine 
are oxidised by both isoforms of the enzyme (Youdim, Finberg, and Tipton, 1988). 
MAO enzyme activity is different in various regions of the brain, where the 
hypothalamus and basal ganglia show the highest activity while the cerebellum and 
neocortex show the lowest activity (O’Carroll et al., 1983). Fowler and company 
mapped the human brain MAO in 1987 to identify the distribution of the MAO 
isozymes throughout the brain and it was found that basal ganglia contain mainly 
MAO-B.  
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2.6.1 STRUCTURE OF MONOAMINE OXIDASE 
a) Monoamine oxidase A 
Human MAO-A contains 527 residues and is specific to serotonin, dopamine and 
norepinephrine. Its active site is formed by a single cavity that extends from the flavin 
ring to the cavity shaping loop of residues 210-216. The volume of this cavity is 
estimated to be approximately 550Å and is lined by 11 aliphatic and 5 aromatic 
residues, which demonstrate that it is hydrophobic (De Colibus et al., 2005). Two 
cysteine residues (Cys 321 and Cys 323) are located near the entry of the catalytic site. 
 
Figure 2.7: Ribbon diagram of a monomer of human monoamine oxidase A with FAD 
(blue) and clorgyline bound oriented as if attached to the outer membrane of 
mitochondrion (RCSB Protein Data Bank). 
The ‘face’ of the covalent FAD is situated at one end of the active site opposite to the 
entrance. It also has two parallel tyrosyl 407 and 444 residues forming an aromatic cage 
in front of the FAD (Edmondson, Binda, and Mattevi, 2007). 
b) Monoamine oxidase B 
Monomaine oxidase B (MAO-B) is made up of 520 amino acids and FAD cofactor. The 
monomer involves a membrane binding domain, a substrate domain and a flavin 
binding domain (Kearney et al., 1971; Binda et al., 2001) MAO-B (Figure 2.8) 
undergoes modification post translation i.e. acetylation where the amino terminal 
methionine is cleaved and the resultant N-terminal serine is acetylated (Li et al., 2002; 
Newton-Vinson, Hubalek, and Edmondson, 2000). It is tightly bound to the outer 
membrane of the mitochondria by the C-terminal amino acids 461-520. Analysis of the 
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enzyme residue sequence revealed that residues 489-515 form a transmembrane helix 
27 amino acids long (Binda et al., 2001). The substrate binding site is formed by a flat 
cavity of 420Å. This cavity is lined by a number of aromatic and aliphatic amino acids, 
providing a highly hydrophobic environment (Walker and Edmondson, 1994). 
Adjoining the substrate cavity is a separate, smaller hydrophobic cavity lined by 
residues Phe 103, Pro 104, Trp 119, Leu 164, Leu 167, Phe 168, Leu 171, Ile 199, Ile 
316 and Tyr 326. This cavity is situated between the active site and the protein surface, 
and is shielded from solvent by loop 99-112 to open access to the smaller entrance 
cavity. The substrate and hydrophobic entrance cavity are separated by residues Trp 
119, Leu 171, Ile 199 and Tyr 326. When a substrate reaches the entrance cavity, a brief 
movement of the four separatory residues must occur to allow its diffusion into the 
active site. Loop 99-112 functions as a sort of gating switch to the entrance cavity 
(Walker and Edmondson, 1994; Binda et al., 2001). 
 
Figure 2.8: Three dimensional structure of human MAO-B monomeric unit in complex 
with 1,4-diphenyl-2-butene. The FAD binding domain (blue), the substrate binding 
domain (red) and the C-terminal membrane binding region is in green. The FAD 
cofactor and the inhibitor are shown as yellow and black ball-stick models, respectively 
(Binda et al., 2003). 
 
In order to covalently bind with the FAD cofactor and undergo metabolism the 
substrate must pass through two hydrophobic cavities, an entrance cavity and a larger 
substrate cavity (Binda et al., 2001). The outer mitochondrial membrane is covered 
with negative charges and these attract amine substrates that are positively charged into 
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the enzyme (Edmondson et al., 2004). The FAD cofactor is located at the end of the 
substrate cavity, covalently bound to the apo-enzyme and considered an important 
component for MAO catalytic activity (Edmondson, 2004). It is of significance to note 
that the amino acids that interact with FAD in the MAO-B enzyme are conserved in 
MAO-A suggesting that FAD is identical in both enzymes (Edmondson, 2004; Kirksey, 
Kwan, and Abell, 1998) 
c) Structural comparison between human MAO-A and MAO-B 
MAO-B has a bipartite elongated cavity that occupies a volume of approximately 700Å 
when the side chain of Ileu199 is in the ‘open’ conformation. MAO-A has a single 
cavity that exhibits a rounder shape compared to that of MAO-B and is larger in volume 
(550 Å) to the substrate cavity of MAO-B which is about 390 Å. QSAR comparison on 
the catalytic properties of the two enzymes showed that the substrate has less freedom 
for rotation in the MAO-B site than the MAO-A (De Colibus et al., 2005; Edmondson, 
Binda, and Mattevi, 2007). Mass spectrometry data have conclusively shown the 
absence of any disulfide bridges in either isozyme (Binda et al., 2003). Although the 
overall chain-folds of the two isozymes are quite similar, there are similarities and 
differences in the respective active sites. The structure of the covalent FAD coenzymes 
and the two tyrosines constituting the aromatic cage in the active sites are identical (De 
Colibus et al., 2005). Since this region is directly involved with substrate oxidation, this 
close similarity supports the notion that both enzymes follow the same catalytic 
mechanisms (Edmondson et al., 2004). However, alterations in the active site residues 
constituting the active site of MAO-A (7 residues are changed in total) and the 
conformation of loop 20-216 cause the shape and sizes of the active sites to differ 
significantly  and are the basis for the specificity of the isozymes (De Colibus et al., 
2005). The entrances to the active sites of either enzyme have been proposed to be at 
the surface of the negatively charged outer membrane which could function to increase 
the effective substrate concentration by electrostatic attraction (Edmondson, Binda, and 
Mattevi, 2007). 
d) Reaction mechanism of MAO 
The MAO enzyme catalyzes the oxidative deamination of primary, secondary and some 
tertiary amines resulting in the formation of hydrogen peroxide, an aldehyde and either 
ammonia (if the substrate in primary amine) or substituted amine in the case of a 
secondary amine(Youdim, Edmondson, and Tipton, 2006; Edmondson et al., 2004). 
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The catalytic mechanism (Figure 2.9) consists of a reductive half reaction where the 
Cα-H bond of the amine is cleaved with the transfer of two reducing equivalents to the 
flavin to form the imine and flavin hydroquinone respectively (Edmondson, 
Bhattacharyya, and Walker, 1993). 
E. FAD red
E.FADox+ S E. FAD redE.FADox- S
E. FAD 
ox
H2O2
Imine
Aldehyde + NH4
Hydrolysis H2O2
Aldehyde + NH4Imine
Key
E. FADred: reduced enzyme + FAD complex
E. FADox: oxidised enzyme + FAD complex
 
Figure 2.9: The catalytic mechanism of MAO 
2.7 TREATMENT OF AD 
The goals of treatment in patients with AD are to improve or slow down the progression 
of the disease, i.e. loss of memory and cognition and to maintain independent function 
(Mayeux and Sano, 1999). Effective treatments are urgently needed. Current drug 
treatment for AD targets cholinergic and glutamatergic transmission to improve disease 
symptoms. In addition, neuroprotective and neurorescue treatment is being investigated. 
 
2.7.1 ACETYLCHOLINESTERASE INHIBITORS 
Identification of the cholinergic component of AD as a major causative pathway 
focused research to the development of inhibitors of the cholinesterase class of 
enzymes. AChE inhibitors in AD act by boosting the endogenous levels of 
acetylcholine in the brain and thereby enhance cholinergic transmission (Talesa, 2001).  
Early research into AChE inhibitors included tetrahydroaminoacridine (tacrine), 
physostigmine and velnacrine. Of the three only tacrine made it to commercial launch, 
followed more recently by donepezil, rivastigmine and metrifonate (B. M. McGleenon, 
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1999). Presently in South Africa registered treatment includes donepezil, rivastigmine 
and galantamine (Figure 2.10) (Rossiter, 2016). 
Tacrine has many actions but prominently acts as a potent reversible cholinesterase 
inhibitor. It is rapidly absorbed and cleared by first pass metabolism in the liver and 
results in hepatotoxicity (McNally et al., 1988; Selen, Balogh, and Siedlik, 1988). The 
bioavailability of tacrine is low upon oral administration and slightly improved with 
high and multiple doses (McNally et al., 1988). It is rapidly absorbed into the brain with 
higher concentrations there than in plasma (Nielsen et al., 1989). 
Taking into account the pharmacokinetic inadequacies of tacrine, donepezil became the 
second AChE inhibitor to be registered with the FDA. It is a rationally designed 
piperadine derivative able to reversibly inhibit AChE with increased specificity than 
tacrine (Sugimoto et al., 1992). 
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Figure 2.10: Structure of AChE inhibitors 
Moreover donepezil lacks activity in peripheral, cardiac and smooth muscle tissue 
making it even more patient friendly. The next drug to highlight is rivastigmine, a brain 
selective carbamate inhibitor of the enzyme. It is known as a pseudo-irreversible 
inhibitor because it mimics acetylcholine in binding with the enzyme and forming a 
carbamylated complex (B. M. McGleenon 1999). This complex formation prevents the 
enzymatic hydrolysis of rivastigmine for several hours post plasma elimination. This, in 
addition, results in an increased duration of action of about 10 hours and consequently 
more side-effects. Physostigmine and galantamine are other known researched 
inhibitors of acetylcholinesterase (B. M. McGleenon, 1999). Unfortunately due to 
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undesirable side effects in small scale clinical trials they were not registered with the 
FDA. However the two serve as scaffolds and lead compounds for continued research 
on the treatment of AD. Treatment with AChE inhibitors has generally been beneficial 
in meliorating a global cognitive dysfunction and, more specifically, are most effective 
in improving attention (Parnetti et al., 1997). AChE inhibitors serve as one aspect of the 
treatment package for AD; they however do not halt the process of apoptosis nor 
improve the depressive symptoms of the disease warranting added therapy. 
2.7.2 NMDA RECEPTOR ANTAGONISTS 
Neuronal death may also be due to over-activation of the N-methyl-D-aspartate receptor 
(NMDAR) that allows influx of calcium ions for normal neuronal function. The 
receptor requires glutamate and glycine as agonists for the activation of ion influx. As 
AD progresses pyramidal neurons of the glutamitergic system diminish hence reducing 
glutamate concentrations in the brain leading to impaired cognition (Wenk, 2006). Over 
excitation of the NMDA receptors ultimately leads to neuronal loss and apoptosis which 
may cause and/or worsen AD (Greenmyre, et al. 1988). Blockers of this receptor have 
been shown to possess neuroprotective capacity and thus serve as therapy and lead 
compounds in the management of AD (Bezprozvanny, 2009). However the blockers of 
this receptor including adamantine and NGP1-01 are associated with adverse central 
nervous effects and this limits their use (Lipton, 2004). Preclinical evidence 
investigating the safety and clinical efficacy of memantine (Figure 2.11) show that it is 
effective for moderate to severe AD and also reverses cognitive impairment (Danysz 
and Parsons, 2003). Memantine is still under further study and is approved in the United 
States, several European countries and South Africa (Memor®) for dementia (Parsons, 
Stöffler, and Danysz, 2007, Rossiter, 2016). 
NH2
 
Figure 2.11: Structure of NMDAR blocker memantine 
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2.7.3 OTHER TREATMENT OPTIONS 
The above discussed classes of drugs are currently registered for the treatment AD and 
as mentioned, they provide only a palliative solution in the management of the disease. 
This however does not mean that research has not produced some potentially successful 
compounds. Due to the multi-factorial nature of AD other targets are currently being 
investigated to combat the disease from all angles. Discussed below are approaches 
under exploration for the treatment of AD. 
2.7.3.1 MONOAMINE OXIDASE INHIBITORS 
There exists a wide range of reversible and irreversible inhibitors of MAO- A and B 
(Table 2.1). They act by inhibiting the activity of the MAO family of enzymes. This in 
turn prevents the breakdown of monoamine neurotransmitters and thereby increasing 
their availability. They have been proven to have therapeutic value in diverse conditions 
including those of neurodegenerative origin (Youdim and Weistock, 2004).  
Table 2.1: Inhibitors of monoamine oxidase and their applications. 
Compound Compound Binding Applications 
Befloxatone A Reversible Antidepressant 
Brofaromine A Reversible Antidepressant 
Clorgyline A Irreversible Antidepressant 
Selegiline B Irreversible Antiparkinsonian 
Iproniazid A and B Irreversible  Antidepressant and anti-TB * 
Isocarboxazid A and B Irreversible Antidepressant 
Lazabemide B Reversible Antiparkinsonian ** 
M30 A and B Irreversible 
Antidepressant, antiparkinsonian and 
anti-Alzheimer 
Moclobemide A Reversible Antidepressant and anxiolytic 
Nialamide  A and B Irreversible Antidepressant* 
PF9601N B Irreversible Antiparkinsonian 
Phenelzine A and B Irreversible Antidepressant 
Rasagiline B Irreversible Antiparkinsonian 
Safinamide B Reversible Antiparkinsonian 
Toloxatone A Reversible Antidepressant 
Tranylcypromine A and B Irreversible Antidepressant and anxiolytic 
*discontinued due to toxicity 
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Rasagiline is currently marketed as Azilect® for Parkinson’s disease. In early literature 
they were reported to have potentially lethal dietary and drug interactions (Blackwell 
and Marley, 1966). Regardless, the propargylamine pharmacophore of this class has 
opened a path to drug design for the treatment of AD. It possesses unique 
neuroprotective ability independent of MAO inhibitory function (Bar-Am et al., 2005). 
N
 
 
Selegiline 
NH
 
Rasagiline 
Figure 2.12: Structure of selegiline and rasagiline, propargylamine highlighted. 
2.7.3.1 ANTI-INFLAMMATORY AGENTS 
Cerebral deposits of Aβ peptides and NFTs are surrounded by inflammatory cells. 
Epidemiological studies have shown that prolonged use of non-steroidal anti-
inflammatory drugs (NSAIDs) reduces the risk of developing AD and delays the onset 
of the disease (Zandi, 2001).  This stems from evidence that NSAIDs preferentially 
reduce the secretion of highly amyloiodogenic Aβ peptide (Zhou et al., 2003). It has 
been postulated that some NSAIDs, such as indomethacin, naproxen and aspirin, target 
pathological hallmarks of AD by interacting with inflammatory pathways such as 
inhibiting cyclooxegenases and activating peroxisome proliferator-activated receptor γ 
(Gasparini, Ongini, and Wenk, 2004). Assessment of the benefit versus side-effects of 
this class of drugs is still ongoing. 
2.7.3.2 ANTI-AMYLOID β THERAPY 
In AD, pathophysiological mechanisms change soluble Aβ peptides into fibrillary 
oligomers and insoluble plaques, which accumulate in the neural tissue and sometimes 
systemic vessels (Solomon, 2009). Toxic Aβ species also trigger secondary pathological 
mechanisms, such as oxidative stress and inflammation, which speed up neuronal 
dysfunction and eventual death (Mathew et al., 2012). Pharmaceuticals that target the 
clearance of Aβ from the brain, inhibit the production, or prevent its aggregation, may 
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represent a strategy to delay the progression of the pathological process of AD. In view 
of this, there exist ongoing clinical trials with humanised monoclonal antibodies like 
bapineuzumab and gantenerumab that target the reduction of Aβ and facilitate its 
clearance from the brain by immune mediated mechanisms (Panza et al., 2011; Burstein 
et al., 2013; Hardy and Selkoe, 2002).  
2.7.3.3 ANTI-OXIDANTS 
With oxidative stress playing a major role in the causation of AD, free radical 
scavenging and antioxidation may prove useful in combating the progression of the 
disease. Ordinarily, one would get sufficient antioxidants from the diet and naturally 
occurring sources or metabolism but when these defences are low, free radicals will 
damage the cell constituents (Coyle and Puttfarcken, 1993).Antioxidant therapy has 
been studied for years as one of the promising therapeutic strategies for AD. Reports 
state that antioxidants such as lipoic acid, vitamin E, vitamin C and β-carotene may help 
break down intra- and extracellular superoxide radicals and H2O2 cell damaging 
compounds (Staehelin, 2005; Grundman, 2000). In 1997 Sano et al. reported that in 
patients with moderately severe AD, treatment with α-tocopherol reduces neuronal 
damage and slows the progression of the disease. Melatonin, an antiamyloiodogenic 
antioxidant that passes the blood brain barrier, is also a direct scavenger on top of its 
ability to protect neurons (Pappolla et al., 2000). 
2.8 MULTITARGET DIRECTED LIGAND 
Over a hundred years since the discovery of the disease by Dr Alois Alzheimer, the 
scientific community still does not fully understand the pathophysiology of AD. It is a 
multifactorial disease caused by various factors including protein misfolding, 
aggregation, oxidative stress, free radical formation and neuro-inflammatoryprocesses. 
These insights together with ongoing research have provided the rationale for therapies 
directly targeting AD molecular causes (Cavalli et al., 2008; Munoz-Torrero and 
Camps, 2006). In the context of such a complex disease it is not insignificant to state 
that these hypotheses are not mutually exclusive but rather complimentary. The 
cholinergic hypothesis has so far produced the majority of drugs approved for treating 
AD together with calcium modulatory compounds (Cavalli et al., 2008).  
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Multiple medication therapy or polypharmacy is a successful concept for diseases like 
cancer where it achieves maximum efficacy by attacking several targets simultaneously, 
exploiting synergy and minimising individual toxicity. Clinically, memantine and an 
acetylcholinesterase inhibitor (rivastigmine, donepezil or galantamine) appear to 
produce an additional effect (Bolognesi et al., 2006; Grossberg, Edwards, and Zhao, 
2006).  However it comes with issues of patient adherence and high cost. Natural 
evolution of the polypharmacy system takes us to the emergence of the multitarget 
directed ligand (MTDL), a relatively novel drug design approach (Zhang, 2005). 
The MTDL strategy is simply a combination of distinct pharmacophores of different 
drugs in the same structure to obtain hybrid molecules. Principally each pharmacophore 
should retain the ability to interact with its specific sites on the target and, consequently, 
produce specific pharmacological responses that slow down or block a 
neurodegenerative process (Pisani et al., 2011). These combinations occur in various 
ways but the most widely adopted is the modification of the molecular structure of an 
AChE inhibitor so as to provide it with additional properties useful for the treatment of 
AD.  
The table below shows results from recent studies on the application of the MTDL 
design strategy. In 2010 Samadi and colleagues successfully synthesised a range of 
tacrine based propargylamine derivatives (Table 2.2). These were then assessed for 
neuroprotective ability against an oxidative stress model. The results showed 
compounds with modest antioxidant activity in the same range as the well-known 
reference N-acetylcysteine. The pharmacophoric group resembling tacrine was able to 
retain the ability to inhibit acetyl- and butyrylcholinesterase. Their results concluded 
that tacrine is a considerable candidate for structural modification for activity on two, or 
possibly more, pharmacological targets that play a role in the progression Alzheimer’s 
disease. 
Memantine is the only polycyclic cage compound currently registered for AD and 
possesses great potential to explore structural modifications. In that line of thought, 
polycyclic cage compounds such as pentacycloundecanes are proven NMDA receptor 
antagonists as well as voltage calcium gated channel blockers that may serve as 
therapeutic agents in neurodegeneration (Geldenhuys et al., 2007). In 2014, Zindo and 
colleagues rationally incorporated these cage moieties and the propargylamine 
http://etd.uwc.ac.za/
  
 
 
 
32 
functional group into novel structures. The resultant compounds portrayed the ability to 
inhibit MAO, block NMDA and calcium channels as well as confer a degree of anti-
apoptotic activity. 
Table 2.2: MTDLs in neurodegeneration 
Dual inhibition strategy Example 
ChE + anti-apotosis 
(Samadi et al., 2010) 
NN NH
CH
NH2
CN
 
MAO + Ca2+ homeostasis 
(Zindo et al., 2014) 
OH
 
MAO + ChE + metal homeostasis  
 (Wang et al., 2014) 
N
N
CN
N
OH
 
Antioxidant + MAO + free radical 
scavenging 
(Perez and Unzeta, 2003) 
N
H
O
NH
CH
 
PF9601N [N-(2-propynyl)-2-(5-benzyloxy-indolyl) methylamine] was the first non-
amphetamine MAO-B inhibitor to be synthesised and has been shown to posses 
neuroprotective properties in models of Parkinson’s disease (Perez and Unzeta, 2003). 
It was also demonstrated to be a good candidate for the treatment of excitotoxicity 
mediated neurodegeneration (Bolea et al., 2014) by its ability to bestow neuroprotective 
ability. Moreover evidence suggests that PF9601N and its metabolites serve as 
exceptional antioxidants (Bellik et al., 2010).  
A large body of evidence exists to support the feasibility of the MTDL paradigm. 
Furthermore one of the most exploited ways to obtain a MTDL is the combination of 
the pharmacophoric features of an acetylcholinesterase inhibitor and a monoamine 
oxidase inhibitor. Pioneering work in the field of hybrid multitarget anti-AD drugs was 
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carried out by Youdim and colleagues (Sterling et al., 2002). They synthesised a large 
series of N-propargylaminoindans and N-propargyl-phenylethylamines as dual 
MAO/AChE inhibitors. The combination of the carbamate moiety of rivastigmine with 
rasagiline led to the compound ladostigil (Sterling et al., 2002). 
NH
ON
O
 
Figure 2.13: Structure of ladostigil, pharmacophores highlighted. 
Ladostigil shown in Figure 2.13 above is able to inhibit both AChE and BuChE for a 
longer duration than the parent compound rivastigmine. This is particularly important 
due to the significance of butrylcholinesterase induced metabolism of acetylcholine 
(Greig et al., 2005). Ladostigil also blocks the activity of brain MAO-A and B resulting 
in an increase in the levels of neurotransmitters like dopamine and thus exerting an 
antidepressant action. It has also been shown to retain the neuroprotective and anti-
apoptotic ability observed in the propargylamine derived parent compound rasagiline 
(Weinstock et al., 2003; Yogev-Falach, 2002; Sagi, Weinstock, and Youdim, 2004). 
Moreover ladostigil also possesses cognition enhancing activity, being the most 
advanced MTDL of this category with promising results obtained from phase 2 clinical 
trials (Youdim et al., 2006). 
2.9 CONCLUSION 
Alzheimer’s disease is a leading causation of morbidity and mortality in today’s society. 
Breakthroughs have been obtained towards its treatment with moderate success in the 
understanding of the pathophysiology and halting the progression of the AD. Pathways 
leading to AD are numerous and varied (multifactorial) and include cascades of 
enzymatic events, genetic mutations and excitotoxicity amongst others. This poses an 
obstacle in drug design and development for management of the disease. Fortunately 
the MTDL paradigm has been established as a promising approach in tackling this 
complex disease. The compounds produced in this project serve as an addition, if not 
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improvement, to the ever growing arsenal of potential multifunctional agents against 
AD. 
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CHAPTER 3 
3. SYNTHETIC PROCEDURES 
3.1 STANDARD EXPERIMENTAL PROCEDURES 
3.1.1 REAGENTS AND CHEMICALS 
All reagents used in the synthesis of compounds were obtained from Sigma-Aldrich® 
(UK) and used without further purification. Solvents used for reactions and 
chromatography were purchased from various commercial sources. 
3.1.2 INSTRUMENTATION 
Nuclear magnetic resonance spectroscopy (NMR): Proton (1H) and carbon (13C) 
spectra were obtained on a 400 MHz Bruker Avance IIIHD Nanobay instrument 
equipped with a 5 mm BBO probe. Tetramethylsilane was used as internal standard, 
with deuterated solvent. All chemical shifts are reported in parts per million using the 
internal standard (δ = 0) and the solvent peaks as reference. The following 
abbreviations are used to indicate the multiplicity of respective signals:  
 s - singlet  
 d - doublet 
 dd - doublet of doublets  
 t – triplet 
 dt – doublet of triplet 
 m - multiplet.  
Infrared absorption spectroscopy (IR): Infrared spectra were obtained on a Perkin 
Elmer Spectrum 400 spectrometer, fitted with a diamond attenuated total reflectance 
attachment.  
Mass spectroscopy (MS): The MS of the samples were obtained with the use of a 
Flexar Single Quad 300 LCMS detector made by Perkin Elmer.  
Melting point determination (MP): MPs were determined by using a Lasec Melting 
Point SMP 10 apparatus and capillary tubes. MPs were determined for the solid forms 
of the final compounds and are specified for each test compound. 
Microwave synthesis: Microwave synthesis was performed using a CEM DiscoverTM 
focused closed vessel microwave synthesis system 
http://etd.uwc.ac.za/
  
 
 
 
36 
3.1.3 CHROMATOGRAPHIC TECHNIQUES 
THIN LAYER CHROMATOGRAPHY (TLC): Analytical TLC was performed on 
0.20 mm thick aluminium silica gel sheets (TLC Silica gel 60 F245 Merck KGaA). 
Visualisation was achieved using UV light (254 nm and 366 nm), with mobile phases 
prepared on a volume-to-volume basis and are specified for each compound 
COLUMN CHROMATOGRAPHY: Impure product was purified using standard 
glass columns varying in size. The stationary phase used was silica gel (0.063 - 0.200 
mm/70 - 230 mesh ASTM, Macherey - Nagel, Duren, Germany) with mobile phases as 
indicated for each compound.  
3.2 SYNTHESIS OF COMPOUNDS 
The synthesis of the proposed compounds was carried out by nucleophilic substitution 
(SN2) of an acyl chloride to the indole polycyclic ring to form the amide and carbamate 
derivatives. This will occur by conjugation of the carbamoyl moiety at either position 5 
or 6 via amidation or esterification followed by the substitution of the propargylamine 
moiety at position 1. Eight compounds were successfully synthesised. The compounds 
were separated into 2 series according to their respective substitutions 
3.3 SYNTHESIS OF COMPOUNDS 1A TO 4A 
The synthetic pathway followed for compounds 1A to 4A is shown in Scheme 1 below. 
The indole was conjugated to the carbamoyl group at position 5 or 6 in a 1:1 ratio, using 
appropriate solvent and 1.2 mmol of potassium carbonate (K2CO3). The mixture was 
stirred for 2 hours at room temperature and monitored using TLC (1 hexane: 2 ethyl 
acetate). Once the reaction was complete the mixture was filtered to remove the K2CO3, 
solvent removed in vacou and the compound extracted at least 3 times with a 
DCM:water mixture. The organic extract was then evaporated and allowed to dry 
rendering the desired compounds. 
Cl
O
N
+
N
H
R
1
N
H
R
2
O
N
 
Scheme 3.1: Synthetic route for the synthesis of Compounds 1A to 4A 
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3.3.1 N,N-diethyl-N'-1H-indol-5-ylurea (1A) 
9
8
4
7
5
6
3
2
N
H
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NH
10
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12
N
13
14
16
17
15
 
Synthesis:In 5 ml acetonitrile, 132.20 mg of 5-aminoindole was dissolved. To the 
mixture 277.5 mg K2CO3 was added. Thereafter 127 µL (135.60 mg) of 
diethylcarbamoyl chloride in 3 ml acetonitrile was added dropwise over 10 minutes. 
The mixture was stirred at room temperature for 2 hours and monitored using TLC (1 
hexane: 2 ethyl acetate).. Once the reaction was complete, K2CO3 was filtered out and 
the acetonitrile removed in vacou. An extraction was carried three times in water:DCM 
(ratio 1:1). The organic phase was washed with a saturated solution on NaCl then again 
with water. The DCM was removed in vacou to render a blackish amorphous product 
which was purified via column chromatography. 
Physical data: C13H17N3O; mass: 198.96 mg; yield: 74.2%; mp: 143 ºC;
1H NMR: 
(400 MHz, CDCl3) ẟH (Spectrum 1): 7.89 (s, 1 H, H – 4), 7.49 - 7.47 (d, 1 H, J = 8.4 
Hz, H – 7), 7.11 – 7.10 (t, 1 H, J = 5.6; 2.8 Hz, H – 2), 6.77 – 6.75 (dd, 1 H, J = 4.8; 2.4 
Hz, H – 6), 6.45 – 6.34 (m, 1 H, H – 3), 3.42 – 3.37 (m, 4 H, H – 14; 16), 1.26 – 1.24 (t, 
6 H, J = 8.0; 4.0 Hz, H – 15, 17); 13C NMR (100 MHz, CD3OD) (Spectrum 2): 158.15, 
137.74, 134.54, 126.26, 125.37, 120.74, 116.81, 106.73, 102.10, 42.43, 14.12;IR (FT – 
IR, cm-1) (Spectrum 3): 3247.42, 2978.13, 1220.22; MS (DI – ESI – MS), m/z, SQ 300 
(Spectrum 4): 232.10 (M+), 233.14, 133.11. 
3.3.2 N,N-diethyl-N'-1H-indol-6-ylurea (2A) 
9
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17  
Synthesis: For the synthesis of 2A, 154.10 mg of 6-aminoindole was reacted with 
325.71 mg K2CO3 and 149 µL (159.08 mg) diethylcarbamoyl chloride under the same 
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conditions as compound 1A. The compound was a brown and oily product which was 
purified via column chromatography. 
Physical data: C13H17N3O; mass: 164.42 mg; yield: 52.5 %; mp: 141 ºC;
1H NMR: 
(400 MHz, CDCl3) ẟH (Spectrum 5): 7.63 (s, 1 H,H – 7), 7.28 - 7.26 (d, 1 H, J = 8.0 Hz, 
H – 5), 7.16 – 7.15 (d, 1 H, H – 4),  6.47 – 6.46 (t, 1 H, J = 4.8; 2.4 Hz, H – 2), 6.26 (m, 
1 H, H – 3), 3.42 – 3.37 (m, 4 H, H – 14; 16), 1.26 – 1.22 (t, 6 H, J = 14.4; 7.2 Hz, H – 
15, 17); 13C NMR (400 MHz, CD3OD) (Spectrum 6):153.69, 126.35, 123.97, 121.48, 
121.23, 114.60, 106.23, 97.42, 79.24, 36.97, 13.41;IR (FT – IR, cm-1) (Spectrum 7): 
3288.30, 2922.65, 1760.52, 1217.09; MS(DI – ESI – MS), m/z, SQ 300 (Spectrum 8): 
232.15 (M+), 226.08, 204.10, 169.08. 
3.3.3 1H-indol-5-yl diethylcarbamate (3A) 
9
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Synthesis:In a round bottomed flask, 60.8 mg of 5-hydroxyindole was dissolved in 
CHCl3/THF (1:1, 10ml). Thereafter 58 µL (61.93 mg) of diethylcarbamoyl chloride in 3 
ml CHCl3/THF was added dropwise over 10 minutes. The mixture was stirred at room 
temperature for 2 hours and monitored using TLC. Once the reaction was complete the 
solvent removed in vacou. An extraction was carried three times in water: DCM (1:1). 
The organic phase was washed with a saturated solution on NaCl then again with water. 
The DCM was removed in vacou to render an orange waxy product.  
Physical data: C13H16N2O2; mass: 100.73 mg; yield: 81.4 %; mp: 126 ºC;
1H NMR: 
(400 MHz, CD3OD) ẟH (Spectrum 9): 7.19 – 7.8 (d, 1 H, J = 8.8 Hz, H – 7), 7.14 - 7.13 
(d, 1 H, J = 2.8 Hz, H – 4), 6.92 – 6.91 (d, 1 H, J = 4.0 Hz, H – 2), 6.60 – 6.40 (dd, 1 H, 
J = 8.8; 2.4 Hz, H – 6), 6.27 – 6.25 (dd, 1 H, J = 3.2; 0.8 Hz; H – 3), 3.21 – 3.16 (m, 4 
H, H – 14; 16), 1.13 – 1.09 (t, 6 H, J =14.4; 6.8 Hz, H – 15, 17); 13C NMR (400 MHz, 
CD3OD) (Spectrum 10):158.38, 137.79, 134.52, 126.28, 125.43, 120.71, 116.83, 
106.66, 102.06, 42.47, 14.13;IR (FT – IR, cm-1) (Spectrum 11):3298.82, 2971.20, 
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1210.75; MS(DI – ESI – MS), m/z, SQ 300 (Spectrum 12): 233.11 (M+), 189.14, 
152.17, 137.40. 
3.3.4 1H-indol-6-yl diethylcarbamate (4A) 
9
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Synthesis: 183.00 mg of 6-hydroxyindole was dissolved in CHCl3/THF (1:1, 10ml). 
Thereafter 116 µL (123.86 mg) of diethylcarbamoyl chloride in 3 ml CHCl3/THF was 
added dropwise over 10 minutes and treated under the same conditions as 3A 
Physical data: C13H17N3O; mass: 245.92 mg; yield: 80.10 %; mp: 159 ºC;
1H NMR: 
(400 MHz, CDCl3) ẟH (Spectrum 13): 7.63 – 7.26 (d, 1 H, J = 1.6 Hz, H – 7), 6.95 – 
6.94 (d, 1 H, J = 2.0 Hz, H – 4), 6.68 – 6.65 (dd, 1 H, J = 8.4; 2.0 Hz, H – 5), 6.48 – 
6.46 (t, 1 H, J = 6.4; 3.2 Hz, H – 2), 6.38 – 6.36 (m, 1 H, H – 3), 3.43 – 3.37 (m, 4 H, H 
– 14; 16), 1.26 – 1.22 (t, 6 H, J =14.4; 6.8 Hz, H – 15, 17); 13C NMR (400 MHz, 
CD3OD) (Spectrum 14): 158.52, 137.78, 134.55, 125.36, 122.75, 120.76, 116.79, 
106.73, 101.26, 42.39, 14.08;IR (FT – IR, cm-1) (Spectrum 15): 3253.61, 1683.13, 
1215.52; MS(DI – ESI – MS), m/z, SQ 300 (Spectrum 16): 233.13 (M+), 152.15, 
135.15. 
3.4 SYNTHESIS OF COMPOUNDS 1B TO 4B 
The second series of compounds (1B to 4B) involved the conjugation of the 
propargylamine moiety to position 1 of the already synthesised 1A to 4A. The reactants 
were mixed in dimethylformamide and left to stir in the microwave for 2 to 4 hours 
with TLC monitoring(1 hexane: 2 ethyl acetate: 1 petroleum ether). Once the reaction 
was complete ice water was added followed by at least 5 extractions with ethyl acetate. 
Thereafter the organic phase was washed with a saturated sodium chloride solution and 
distilled water again. The ethyl acetate was removed in vacou to render pure product. 
The reaction is summarised in Scheme 3.2 below. 
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Scheme 3.2: Synthetic route for the synthesis of compounds 1B to 4B. R = O/NH 
3.4.1 N,N-diethyl-N'-[1-(prop-2-yn-1-yl)-1H-indol-5-yl]urea (1B) 
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Synthesis: In a microwave compatible glass-vessel, 50.00 mg of 1Awas dissolved in 
DMF (6 ml) and treated with NaH (60 %, 40 mg, 1 mmol). The mixture was stirred at 
room temperature for 10 minutes followed by the addition of excess propargyl bromide 
solution (35.36 µL, 28.29 mg) while stirring. Subsequently the vessel was sealed and 
the mixture was stirred at 95 ºC for 2.5 hours using microwave irradiation (maximum 
power = 150W). Thereafter the mixture was added to 60 ml water, extracted with 100 
ml ethyl acetate, washed with saturated NaCl solution and then washed 3 times again 
with water and dried in vacou to render a black amorphous powder. 
Physical data: C16H19N3O; mass: 74.39 mg; yield: 95.02 %; mp:158 ºC;
1H NMR: 
(400 MHz, CDCl3) ẟH (Spectrum 17): 7.64 – 7.63 (d, 1 H, J = 1.6 Hz, H – 4), 7.29 – 
7.27 (d, 1 H, J = 8.8 Hz, H – 7), 7.15 – 7.14 (m, 2 H, J = 10.4 Hz, H – 2, 6), 6.47 – 6.46 
(t, 1 H, J = 1.0, 2.0 Hz, H – 3), 4.12 (s, 2 H, H – 18),  3.42 – 3.37 (m, 4 H, H – 14; 
16),2.22 (s, 1 H, H – 20), 1.26 – 1.23 (t, 6 H, J =14.0; 6.8 Hz, H – 15, 17); 13C NMR 
(400 MHz, CD3OD) (Spectrum 18):157.03, 153.96, 147.94, 139.35, 126.21, 120.56, 
111.42, 114.78, 110.24, 109.63, 105.20, 97.47, 43. 55, 11.50;IR (FT – IR, cm-1) 
(Spectrum 19): 3293.69, 2922.34, 1761.13, 1217.23; MS (DI – ESI – MS), m/z, SQ 300 
(Spectrum 20): 270.94, (M+), 236.89, 228.97, 214.00. 
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3.4.2 N,N-diethyl-N'-[1-(prop-2-yn-1-yl)-1H-indol-6-yl]urea (2B) 
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Synthesis: For the synthesis of 2B, 65.20 mg of 2A (N,N-diethyl-N'-1H-indol-6-ylurea) 
was reacted with 46.11 µL (36.89 mg) propargyl bromide under the same conditions as 
compound 1B. 
Physical data: C13H17N3O; mass: 89.77 mg; yield: 87.93 %; mp: 166 ºC;
1H NMR: 
(400 MHz, CD3OD) ẟH (Spectrum 21): 7.42 – 7.40 (m, 2 H, H – 7,4), 7.15 – 7.14 (d, 1 
H, J = 3.8 Hz, H – 3), 6.94 – 6.92 (d, 1 H, J = 8.4 Hz, H – 5), 6.37 – 6.36 (d, 1 H, J = 
3.2 Hz, H – 2), 4.61 (s, 2 H, H – 18), 3.46 – 3.41 (m, 4 H, H – 14, 16), 2.16 (s, 1 H, H – 
20); 1.23 – 1.19 (t, 6 H, J =14.4; 6.8 Hz, H – 15, 17); 13C NMR (400 MHz, CD3OD) 
(Spectrum 22): 157.13, 139.29, 127.18, 126.16, 120.56, 114.69, 110.23, 109.85, 105.26, 
102.33, 97.49, 43.46, 11.61;IR (FT – IR, cm-1)(Spectrum 23): 3300.95, 3194.06, 
2927.43, 1210.50; MS (DI – ESI – MS), m/z, SQ 300 (Spectrum 24): 271.15 (M+), 
255.10, 233.11, 114.66. 
3.4.3 1-(prop-2-yn-1-yl)-1H-indol-5-yl diethylcarbamate (3B) 
9
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Synthesis: For the synthesis of 3B, 71.66 mg of 3A (1H-indol-5-yl diethylcarbamate) 
was reacted with 43.37 µL (34.69 mg) propargyl bromide under the same conditions as 
compound 1B. 
Physical data: C16H18N2O2; mass: 100.39 mg; yield: 94.4 %; mp: 187 ºC;
1H NMR: 
(400 MHz, CD3OD) ẟH (Spectrum 25): 7.50 – 7.46 (d, 1 H, J = 16.0 Hz, H – 7), 7.24 – 
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7.19 (dd, 2 H, J = 19.2; 3.2 Hz, H – 4, 6), 7.16 – 7.13 (dd, 1 H, J = 10.4; 1.6 Hz, H – 2), 
6.41 – 6.37 (dd, 1 H, J = 15.6; 2.8 Hz, H – 3),4.96 – 4.95 (d, 2 H, H – 18);  3.45 – 3.40 
(m, 4 H, H – 14; 16), 2.79 – 2.78 (t, 1 H, J = 4.8; 2.4 Hz, H – 20), 1.23 – 1.19 (t, 6 H, J 
=14.4; 7.2 Hz, H – 15, 17);13C NMR (400 MHz, CD3OD) (Spectrum 26): 158.52, 
135.13, 132.06, 129.38, 125.73, 120.36, 116.34, 114.23, 111.79, 107.90, 102.34, 
101.38, 42.32, 14.13;IR (FT – IR, cm-1) (Spectrum 27): 3299.52, 3195.74, 1210.83; MS 
(DI – ESI – MS), m/z, SQ 300 (Spectrum 28): 271.11 (M+), 236.02, 202.03 115.05. 
3.4.4 1-(prop-2-yn-1-yl)-1H-indol-6-yl diethylcarbamate (4B) 
9
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Synthesis: For the synthesis of 4B, 63.95 mg of 4A (1H-indol-6-yl diethylcarbamate) 
was reacted with 38.69 µL (30.95 mg) propargyl bromide under the same conditions as 
compound 1B. 
Physical data: C16H18N2O2; mass: 90.48 mg; yield: 95.34 %; mp: 168 ºC;
1H NMR: 
(400 MHz, CD3OD) ẟH (Spectrum 29): 7.47 – 7.46 (dd, 1 H, J = 4.0, 2.0 Hz, H – 7), 
7.39 – 7.36 (d, 1 H, J = 12.0 Hz, H – 4), 7.24 – 7.23 (d, 1 H, J = 4.0 Hz, H – 5), 7.20 – 
7.19 (d, 1 H, J = 4.0 Hz, H – 2), 6.43 – 6.33 (m, 1 H, H – 3), 4.96 – 4.95 (d, 2 H, J = 4.0 
Hz, H – 18);  3.46 – 3.40 (m, 4 H, H – 14,16), 2.79 – 2.70 (t, 1 H, J = 8.0; 4.0 Hz, H – 
20), 1.23 – 1.21 (t, 6 H, J = 8.0; 4.0 Hz, H – 15, 17); 13C NMR (400 MHz, CD3OD) 
(Spectrum 30):158.76, 135.15, 132.05, 129.32, 126.16, 126.08, 124.58, 119.97, 116.27, 
111.79, 102.32, 101.29, 42.52, 14.14; IR (FT – IR, cm-1) (Spectrum 31): 3291.83, 
2922.52, 1761.08, 1217.03; MS (DI – ESI – MS), m/z, SQ 300 (Spectrum 32): 271.59 
(M+), 236.01, 228.96, 115.06. 
3.5 CONCLUSION 
Eight compounds were successfully synthesised. The compounds in the first series i.e. 
carbamate derivatives (1A, 2A, 3A, 4A) were mostly impure with percentage yields 
ranging between 50 and 80 %. The second series (1B, 2B, 3B, 4B) was synthesised 
under microwave irradiation conditions that improved yield and efficiency. All 
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compounds were successfully elucidated via NMR, IR and the molecular masses 
confirmed using MS. The compounds were then analysed for biological activity in vitro 
and the results are discussed in Chapter 4.The compounds were also susceptible to light 
degradation hence required storage in dark, cool environments.   
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CHAPTER 4 
4. MOLECULAR MODELLING AND BIOLOGICAL 
EVALUATION 
4.1 INTRODUCTION 
The medicinal chemistry and therapeutic potential of MTDL has been extensively 
explored by a number of research groups. This has led to the development of a variety 
of potential multifunctional neuroprotective compounds. Studies have shown the 
significance of the carbamoyl moiety of rivastigmine for cholinesterase inhibition 
(Gavrilova et al., 1999; Enz et al., 1993), the propargylamine group of selegiline and 
rasagiline for MAO inhibitory activity and neuroprotection (Zindo, et al., 2015) and the 
indole heterocyclic moiety for MAO and NOS inhibition and neuroprotection (Stolc et 
al., 2006; Buemi et al., 2013). As discussed earlier the MTDL strategy has become 
popular in designing compounds able to treat the multifactorial nature of Alzheimer’s 
disease. This approach also avoids the application of polypharmacy which is costly both 
to the patient and the economy and comes with compliance issues (Cavalli, et al., 
2008). 
The aim of this study was to design and synthesise a series of novel indole derivatives 
and to evaluate them for AChE, BuChE, MAO-A and MOA-B enzyme inhibition. 
Molecular modelling and four assays were conducted to achieve this aim. We 
hypothesised that the 8 compounds, successfully synthesised (Table 4.1), would exert 
promising results on all relevant assays. 
4.2 MOLECULAR MODELLING 
Molecular modelling is a frequently used tool in structure based rational drug design. 
Docking programs such as AutoDock, Molecular Operating Environment (MOE) and 
SURFLEX – DOCK simulate how a target macro-molecule such as a receptor or 
enzyme interacts with small molecule ligands (substrates, inhibitors etc.). To model the 
binding between the ligand and the target molecule, the known three dimensional 
structures are super-imposed (docking) and the interactions between the two is then 
analysed.  In this study we utilised MOE 2015 to model the binding of our potential 
inhibitors to co-crystallised forms of AChE, MAO-A and MAO-B. 
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Table 4.1: Successfully synthesised compounds assayed for activity and the controls 
1A 
N
H
NH
O
N
 
N,N-diethyl-N'-1H-indol-5-ylurea 
2A N
H
NH
O
N
 
N,N-diethyl-N'-1H-indol-6-ylurea 
3A 
N
H
O
O
N
 
1H-indol-5-yl-diethylcarbamate 
4A N
H
O
O
N
 
1H-indol-6-yl-diethylcarbamate 
1B 
N
NH
O
N
 
N,N-diethyl-N'-[1-(prop-2-yn-1-yl)-1H-indol-5-yl]urea 
2B 
NNH
O
N
 
N,N-diethyl-N'-[1-(prop-2-yn-1-yl)-1H-indol-6-yl]urea 
3B N
O
O
N
 
1-(prop-2-yn-1-yl)-1H-indol-5-yl-diethylcarbamate 
4B 
NO
O
N
 
1-(prop-2-yn-1-yl)-1H-indol-6-yl-diethylcarbamate 
Tacrine 
N
NH2  
1,2,3,4-tetrahydroacridin-9-amine 
Rasagiline NH
 
(1R)-N-(prop-2-yn-1-yl)-2,3-dihydro-1H-inden-1-amine 
Clorgyline 
O N
Cl
Cl
 
N-[3-(2,4-dichlorophenoxy)propyl]-N-methylprop-2-yn-
1-amine 
Ladostigil NH
ON
O
 
(3R)-3-[(prop-2-yn-1-yl)amino]-2,3-dihydro-1H-inden-
5-yl ethyl(methyl)carbamate 
http://etd.uwc.ac.za/
  
 
 
 
46 
4.2.1 MOLECULAR MODELLING METHODS 
The necessary enzyme complexes were obtained from the PSLIO / PDB databank. The 
codes for the enzymes used were 1EVE for AChE co-crystallised with donepezil, 2v5z 
for MAO-B co-crystallised with safinamide and 2BXR for MAO-A co-crystallised with 
clorgyline. Prior to docking, the enzymes were protonated and cleaned up for any 
unnecessary amino acids surrounding the binding sites, while maintaining the integrity 
of the enzyme backbone. This helps to make the viewing of the interactions easier. The 
existing ligand, was then selected in order to specify the binding pocket of the enzyme. 
The energy minimised compounds (V3000 MDL molfiles drawn using Chemsketch) 
were then docked using the induced fit protocol. We discuss below the results that of 
selected compounds that showed the lowest binding energy and best fit during 
molecular docking. 
4.2.2 ACHE DOCKING RESULTS 
AChE contains two subsites; the PAS and CAS sites as well as a gorge lined with 
aromatic amino acids connecting the two (Colovic et al., 2013). It was expected that the 
carbamate/urea component of the molecule will possess interactions in the CAS and the 
rest of the molecule with the PAS (Jampilek et al., 2012). 
The results showed that the compounds interacted with the whole cholinesterase active 
site. The alkyl component of the carbamate moiety of the compounds (1A, 2A and 4B) 
showed π – H interactions with Trp 84 in the CAS as can be seen in Figure 4.1 below. 
This interaction has been reported to be very crucial in AChE inhibitory activity 
(Tougu, 2001). 
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H
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H
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O
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2A 
 
4B 
 
Figure 4.1: Docking pose of compounds 1A, 2A and 4B in AChE active site. The 
ligand is shown in yellow and AChE residues in green. 
 Compounds 4A, 2B and 3B possessed π – π interactions between the indole polycyclic 
ring and Trp 279 in the PAS site (Figure 4.2). Moreover compound 4A possessed π – H 
interactions with Phe 330, a key residue involved in ligand binding in the active gorge. 
We can surmise that compounds 4A, 2B and 4B would possess good AChE inhibitory 
activity. It is important to note that the propargylamine moiety did not show any 
significant interaction with amino acids in the active site. The moiety occupied the 
gorge (4B) facing the PAS 
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2B 
 
3B 
 
Figure 4.2: Docking pose of compounds 4A, 2B and 3B in the AChE active site. 
4.2.3 MAO DOCKING RESULTS 
A review of the MAO-A enzyme showed that it exists as a monomer that is highly 
inhibited by clorgyline (De Colibus et al., 2005).  
Docking studies showed that the compounds possessed little interaction with the amino 
acids in the MAO-A active site. The results showed that the carbamylated compounds 
1A- 4A lacked interactions with vital residues in the active site such as Phe 208 and the 
FAD cofactor. We observed that for these compounds the indole polycyclic ring was 
best orientated towards the FAD cofactor in the substrate cavity (Figure 4.5) except for 
2A.They also had hydrogen bonds with the water molecules in the substrate cavity. 
From these observations these compounds did not appear to be good inhibitors of the 
enzyme. We observed that the urea component of compound 2A was oriented towards 
the substrate cavity. This allowed it to have non – covalent interactions with Tyr 407 
and Gln 215 in the active site unlike the other compounds. 
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1A 
 
3A 
 
4A 
 
Figure 4.5: Docking pose of compounds 1A, 3A and 4A in the MAO-A active site. The 
ligand is shown in yellow, the FAD in purple and the rest of the molecule in grey. 
The compounds that contained the propargylamine moiety were not aligned in a manner 
that we expected i.e. with the moiety in close proximity to the FAD cofactor with the 
rest of the molecule occupying the active site. Compound 2B was the only compound 
that had the propargylamine oriented in the direction of the FAD as seen in Figure 4.6.  
This has been reported to be essential for MAO inhibitory capacity (Edmondson, 2004), 
thus the compound may prove to be a good inhibitor of the enzyme.  The indole 
polycyclic ring did not portray any significant interactions with the MAO-A active site, 
but the compounds seem to sit well in the active site.  
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2B 
 
Figure 4.6: Docking pose of compounds 2B in the MAO-A active site. 
All the above mentioned compounds had interactions with Cys 323 via the carbonyl 
group of the carbamate component of the molecule. This is one of the residues that line 
the entrance to the catalytic site of the MAO-A enzyme (De Colibus et al., 2005). This 
indicates that these compounds enter the active site even though they do not have the 
desired interactions to portray good activity. The rest of the compounds had little to no 
interactions in the active site and so may not be good inhibitors of the MAO-A enzyme. 
With regards to MAO-B molecular docking experiments we expected specific 
interactions between the compounds and the FAD co-factor, rather we observed that 
compounds 1A, 2A, 3A and 4A had π – H interactions with the gating residue Ile 199 
meaning they do enter the active site to the hydrophobic cavity but perhaps do not reach 
the substrate cavity. The compounds were not in close proximity to the FAD cofactor 
which is essential for good activity (Figure 4.7). The indole polycyclic ring  of these 
compounds did not show any interactions, except in the case of compound 2A that 
interacted with Cys 172. This may indicate that that 2A could possess better MAO-B 
inhibitory activity compared to the other three. 
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3A 
 
4A 
 
Figure 4.7: Docking pose of compounds 2A, 3A and 4A in the MAO-B active site. The 
ligand is shown in yellow, the FAD in red and the rest of the molecule in grey 
The propargylamine containing compounds showed better interactions. The moiety was 
aligned much closer to the FAD with different compounds showing various interactions 
with Leu 171 (1B), Tyr 326 (2B) and Tyr 398 (3B). Compound 2B was aligned closest 
to the FAD as seen in Figure 4.8 and so may prove to have good inhibitory activity. It 
also showed interactions with Tyr 326, a residue that contributes to substrate specificity. 
This leads us to ascertain that the compound may be more selective to MAO–B. 
2B 
 
Figure 4.8: Docking pose of compounds 2B in the MAO-B active site 
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4.3 CHOLINESTERASE ASSAY 
AChE and BuChE efficiently catalyse the hydrolysis of acetylthiocholine, a sulphur 
analog of the natural substrate (acetylcholine) of these enzymes. Upon hydrolysis, the 
acetylthiocholine breaks down into acetate and thiocholine. Thiocholine, in the presence 
of the highly reactive dithiobisnitro-benzoate (DTNB) ion generates a yellow colour, 
which can be quantitatively monitored by spectrophotometric absorption at a 
wavelength of 405 nm. In this assay, acetylthiocholine and butyrylthiocholine were 
used as substrates for AChE and BuChE respectively. This method was first described 
by Ellman and colleagues (1961) and has been optimised over the years (Riddles, 
Blakeley, and Zerner, 1979). AChE form electric eel and BuChE of equine origin were 
used. 
4.3.1 CONSUMABLES AND INSTRUMENTATION 
Unless otherwise stated, all chemicals and reagents used for this assay were purchased 
from SigmaAldrich. A Rayto 6500 microplate reader was used to read the intensity of 
colour change at a wavelength of 405 nm. A pH meter was used to determine the pH of 
the assay buffer. Finally data analysis was carried out using Graph Pad Prism 7. 
4.3.2 EXPERIMENTAL PROCEDURES 
Stock solutions of test compounds and controls (tacrine for both cholinesterase 
enzymes) were prepared by dissolving the test compounds in dimethyl sulfoxide 
(DMSO) and were kept under refrigeration until use. Stock solutions were made at 10 
mM concentrations and further serial diluted to achieve final concentrations of 100µM, 
10 µM, 1 µM, and 0.1 µM. The buffer, trizma hydrochloride, was prepared in water at a 
concentration of 50 mM with the pH adjusted to 8 using diluted 1N sodium hydroxide. 
It was also refrigerated until use. The trizma hydrochloride was used to prepare 1.5 mM 
DTNB, 15 mM acetylthiocholine iodide, 15 mM butyrylthiocholine iodide, 22 units/ml 
electric eel AChE stock solution and 12 units/ml equine BuChE stock solution. The 
enzyme stock solutions were stabilised with 1% bovine serum albumin and stored in 
aliquots at -80 ºC. 
A clear, flat base 200 µL 96 well plate was used. Prior to the experiment the enzyme 
stock solution was diluted to 0.22 units/ml AChE and 0.12 units/ml BuChE. Each plate 
row consisted of a background control (no compound), a positive control (tacrine) and 8 
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wells of test compounds. DTNB (148 µL) and 50 µL enzyme solution was added into 
the required well on the plate. DMSO (2 µL) was added to the background control well, 
2 µL tacrine for positive control followed by 2 µL test compound in consecutive wells. 
The plate was then incubated at 25 ºC for 10 minutes. Using a micropipette, 30 µL of 
the substrate was added simultaneously to all wells. The well plate was further 
incubated for another 10 minutes at 25 ºC. Thereafter absorbance was read at 405 nm 
using a Rayto 6500 spectrophotometer. The data obtained was used to calculate 
percentage cholinesterase inhibition and plot dose-response curves using Graph Pad 
Prism 7 software which was then used to extrapolate IC50 values. All experiments were 
done in triplicate. It is important to note that DMSO may influence assay readings 
hence the necessity to keep it constant and less than 1 %. At a 1 % concentration the 
DMSO did not influence the assay results. 
4.3.3 RESULTS AND DISCUSSION 
Previous studies have shown that the carbamoyl moiety of FDA approved dual 
cholinesterase inhibitor rivastigmine (Figure 2.7) is important in its action against 
cholinesterase enzymes. We applied this logic by attaching the carbamoyl moiety via an 
SN2 nucleophilic reaction to the 5 or 6 position of the indole polycyclic ring to render 
compounds 3A, 4A, 3B, 4B.We also explored a series of urea based compounds that 
have an amide linkage at position 5 or 6 (1A, 2A, 1B, 2B) to observe how this change 
would affect activity. We expected all the compounds to have some degree of inhibitory 
activity towards the enzymes. Figure 4.3 below highlights the results of the AChE 
assay with a p-value below 0.05.The p-value expresses the statistical validity of the data 
used to plot the curves. A desirable p-value is below 0.05 which means the data is 
statistically significant (Nuzzo, 2014). A one-way ANOVA statistical analysis was done 
using Graphpad Prism 7 to calculate the p values. 
As can be observed all the compounds were able to inhibit AChE with IC50 values 
between 1 M and4 µM. This illustrates that the diethylcarbamoyl moiety both as a 
carbamate or urea bond contributes to inhibition of the AChE enzyme. These results 
also support the docking observations. Literature reports indolyl alkaloids and their 
metabolites to exert good cholinesterase inhibitory capacity amongst other functions 
(Ismail et al., 2012; Passos et al., 2013). The docking results showed some interactions 
between the indole polycyclic ring and the amino acids lining the entrance of the active 
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site. As a result we also speculate that the indole polycyclic ring may have contributed 
to some inhibitory capacity of the compounds. Also, the compounds exerted good 
activity regardless of the position of the carbamoyl moiety, whether it’s a carbamate or 
urea based compound or whether it contains the propargylamine moiety or not. 
Compound 1A had the lowest IC50 of 1.97 µM. These results agree with some of the 
modelling results where we observed that the carbamoyl and urea moieties interact with 
important residues in the CAS and the rest of the molecule fits in the (PAS) similar to 
rivastigmine (Greenblatt et al., 2003).Addition of the propargylamine moiety did not 
affect the inhibitory capacity of the compounds showing again that the carbamate and 
urea moieties are highly involved in activity. 
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Figure 4.3: Non-linear regression curves for AChE activity for the tested compounds 
(1A – 4B) and tacrine. IC50 values are shown. 
Comparing the IC50 values of the test compounds to that of tacrine (6.17 µM) shows 
that the test compounds are good inhibitors of the enzyme and are equally as potent as 
tacrine. The IC50 of tacrine was in the same range as reported by Chao et al., 2012. 
Literature reports the IC50 of rivastigmineas501µMon electric eel AChE (Imramovsky 
1A 
IC50 = 1.97 µM 
IC50 = 2.77 µM 
IC50 = 2.28 µM 
IC50 = 3.70 µM 
1B 
2A 
2B 
3A 
IC50 = 2.78 µM 
IC50 = 3.72 µM 
IC50 = 2.57 µM 
3B 4B 
IC50 = 2.41 µM IC50 = 6.17 µM 
TAC 
4A 
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et al., 2012). These studies suggest that the synthesised compounds are almost 100 
times more potent than rivastigmine on the same species of AChE.  
The role that BuChE plays in the progression of AD is its ability to hydrolyse 
acetylcholine in the event of AChE saturation (Giacobini, 2004). Accordingly a 
compound that inhibits this enzyme, in addition to AChE, would prove beneficial for 
the treatment of AD. We therefore went on to assay our compounds for BuChE 
inhibitory activity and the results are summarised in Figure 4.4.The IC50 values of the 
compounds were also compared to tacrine. 
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Figure 4.4: Non-linear regression curves for BuChE activity for the tested compounds 
and tacrine as control. IC50values are shown. 
These results showed that the synthesised compounds had good activity in inhibiting 
this enzyme. The IC50 values, as can be seen from Figure 4.4 above, ranged between 2 
and 5 µM. The compounds also showed activity in the same range as tacrine. 
Carbamoyl containing compounds have also been shown to be BuChE enzyme 
substrates (Colovic et al., 2013) so we postulate that the diethylcarbamoyl moiety 
interacts with the enzyme structure to block its catalytic activity. Molecular modelling 
was not carried out on this enzyme; hence we can only hypothesize that the carbamoyl 
1A 
3A 
2B 
3B 
1B 
2A 
4A 
4B 
TAC 
IC50= 3.48 µM IC50 = 4.55 µM IC50 = 2.29 µM 
IC50 = 3.18 µM 
IC50 = 3.96 µM IC50 = 2.82 µM 
IC50 = 3.01 µM IC50 = 3.78 µM IC50 = 1.48 µM 
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and perhaps the indole polycyclic ring might have an interaction in the active site to 
inhibit ACh hydrolysis. 
Rivastigmine was reported to inhibit 50 % of the enzyme at a concentration of 19.95 
µM and 37 nM in equine and human BuChE respectively (Krátký et al., 2016; Luo et 
al., 2006).We can see that all the synthesised compounds have higher activity than 
rivastigmine in equine BuChE and evaluation in human BuChE is thus essential. 
When we evaluate the different substitutions of the test compounds, we see that the 5 
substituted compounds yielded similar results compared to the 6 substituted 
compounds. Compounds 1A, 2A, 1B and 4B showed a slight selectivity towards AChE 
and the other compounds exhibited an equivalent activity for BuChE and to AChE. 
Selectivity indices were close enough for the compounds to be classified as non-
selective ChE inhibitors in vitro. 
Table 4.2:IC50and selectivity indices of the compounds towards ChE
1 
Compound ID AChE (µM) BuChE (µM) SI {
    
     
} 
1A 1,97 3,48 0.57 
2A 2,28 4,55 0.50 
3A 2,77 2,29 1.21 
4A 3,72 3,18 1.17 
1B 2,77 3,96 0.70 
2B 3,70 2,82 1.31 
3B 2,57 3,01 0.85 
4B 2,41 5,01 1.48 
Ladostigil 31.80 1.98 16.06 
Rivastigmine* 56.10 19.95 2.81 
*ChE inhibitory activity of rivastigmine as reported by Krátký, et al., 2016b. 
We can conclude that the compounds are good dual ChE inhibitors able to reduce the 
hydrolysis of AChE. They also show a good balance between AChE and BuChE 
activities. Importantly, the compounds portray non-selective inhibitory activities 
compared to ladostigil which is 16 times more selective towards AChE. Moreover 
literature has reported that AChE promotes the assembly of Aβ into amyloid fibrils and 
that compounds that interact well with the PAS may inhibit this effect (Inestrosa et al., 
                                                          
1 The selectivity index (SI) of the compound is a ration of the compounds selectivity to one site compared 
to the other, and is calculated by dividing the IC50 values. 
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1996, Reyes et al., 1997). These compounds may also prove to reduce the 
conglomeration of amyloid fibrils into plaques in addition to reducing Ach hydrolysis. 
4.4 MAO ASSAY 
The MAO assay measures the ability of the compounds to inhibit the isozymes MAO-A 
and MAO-B and reduce the metabolism of amine neurotransmitters. The concept of this 
assay (Figure 4.9) involves the ability of MAO to convert the non-fluorescent and non-
selective substrate, kynuramine, into fluorescent 4-hydroxyquinoline (Krajl, 
1965).Kynuramine is the substrate in place of naturally occurring neurotransmitters 
such as dopamine.  In the presence of an inhibitor, there is reduced interaction of 
kynuramine with the enzyme thus reduction in the fluorescence level (in comparison to 
a blank) indicates activity. Figure 4.9 highlights the basic principle of this assay (Yan 
et al., 2004). 
NH2
O
NH2
O
O
NH2
N
H
O
OH
N
OH
Kynuramine
4-hydroxyquinoline
 
Figure 4.9: Principle of MAO catalysed conversion of kynuramine. 
The fluorescence values obtained were used to calculate the percentage enzyme 
inhibition, plot dose-response curves and to extrapolate IC50 values. As with the ChE 
assay a p-value below 0.05 is desirable implying statistical significance and 
reproducibility of the results. 
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4.4.1 CONSUMABLES AND INSTRUMENTATION 
Unless otherwise stated, all chemicals and reagents used for this assay were purchased 
from Sigma Aldrich. A SynergyMx Biotek spectrophotometer was used to read the 
fluorescence intensity at an excitation wavelength of 310 nm and emission of 410 nm. 
A pH meter was used to determine the pH of the assay buffer. Finally data analysis was 
carried out using Graph Pad Prism 7. 
4.4.2 EXPERIMENTAL PROCEDURES 
Stock solutions of the test compounds and controls (clorgyline for MAO-A and 
rasagiline for MAO-B) were prepared by dissolving the test compounds in DMSO and 
it was kept under refrigeration until use. The solutions were made at 10 mM 
concentrations and further serial diluted to achieve final concentrations of 100 µM, 10 
µM, 1 µM, 0.1 µM and 0.01 µM. The potassium phosphate buffer was prepared in 
water at a concentration of 100 mM (adjusted to pH 7.4 by 2N NaOH). It was also 
refrigerated until use. The stock solution of the substrate kynuramine was made at 750 
µM (45 µM final assay concentration) for MAO-A and 500 µM(30 µM final assay 
concentration) for MAO-B. Fresh substrate was prepared for each day to ensure that the 
activity was sustained. Using the phosphate buffer, MAO enzyme stock solution was 
prepared and stored in aliquots at -80 ºC until use to avoid thermal induced 
deactivation. 
The assay was carried out in eppendorf vials and needed an incubator oven set at 37 ºC. 
To each vial 207.5 µL of phosphate buffer and 2.5 µL of corresponding test compound 
or control compound was added. This was followed by 25 µL of the enzyme at 10 
second intervals. The mixture was then incubated for 10 minutes at 37 ºC. Thereafter 15 
µL of kynuramine (45 µM for MAO-A and 30 µM for MAO-B) was added also at 10 
second intervals and it was then further incubated for 20 minutes. 150 µL of 2 N NaOH 
were used to stop the reaction. The mixture was well shaken after each addition. Finally 
200 µL of the mixture was added to each well of a black 96 well plate, placed in the 
fluorescent plate reader and read at excitation/emission wavelength of 310 nm/400 nm. 
Each assay was run in triplicate and the data was analysed with Graph Pad Prism 7 
software. 
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4.4.3 RESULTS AND DISCUSSSION 
The results (Figure 4.10) show that all the compounds but 1A had the ability to inhibit 
the MAO-A enzyme at concentrations below 100 µM. As observed from the IC50 values 
the compounds that did not possess the propargylamine moiety had, in general, lower 
activity compared to the propargylamine. Compounds 2A and 3A were the exceptions, 
showing significantly low IC50 values. The modelling results showed that the 
compounds’ indole ring had interactions with some water molecules in the substrate 
cavity and this may contribute to activity. Compound 2A had a different orientation in 
the active site of MAO–A but it portrayed a relatively low IC50.  
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Figure 4.10: Non-linear regression curves for MAO-A activity for the tested 
compounds and clorgyline as control. IC50values are shown 
Literature suggests that the propargylamine moiety is responsible for the MAO 
inhibitory properties of compounds containing this moiety (Bar-Am et al., 2005).The 
results obtained agree with this, as can be seen by the lowering of the IC50 value (i.e. 
increase in potency) upon conjugation of the moiety. The presence of a urea moiety 
(compounds 1B and 2B) resulted in compounds that have comparably better inhibitory 
abilities than the carbamate linked compounds 3B and 4B. This permits us to assume 
3A 
2B 4A 1B 
2A 
3B 
4B 
CLO 
1A 
IC50 = >100 µM IC50 = 20.37 µM IC50 = 13.15 µM 
IC50 = 88.11 µM IC50 = 33.42 µM IC50 = 4.31 µM 
IC50 = 99.08 µM IC50 = 51.64 µM 
IC50 = 0.31 µM 
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that the hydrogen donating ability of the secondary amine in the urea moieties may 
contribute to important interactions with amino acids in the active site of the enzyme. 
Looking at the results overall the compounds were moderately good inhibitors of the 
MAO-A enzyme. None of the compounds showed activity in the same range as 
clorgyline. Clorgyline was used as the control for MAO-A due to its high potency 
inhibitory capacity 
Compound 2B had the lowest IC50within the series (4.31 µM) towards MAO-A. It 
possesses the carbamoyl substitution at position 6 and the propargylamine at the N1 
position. The docking results support this activity where 2B was observed to have the 
best interactions with the enzyme compared to the other compounds. The comparable 
compound 4B with similar orientation except for a carbamate bond instead of the urea 
conjugation is 12 times less potent towards the same enzyme. 
With regards to MAO – B inhibition, rasagiline was as positive control for comparison. 
It was observed that compounds 1A, 2A, 3A and 4A had IC50 values above 100 µM 
(Figure 4.11). These were the compounds that did not possess the propargylamine 
substitution at position 1 and we may surmise that they lacked vital interactions with the 
FAD co-factor. The docking results did show such lack of interactions within the active 
site. With further conjugation of the propargylamine moiety, a significant increase in 
the potency of these compounds against the enzyme was observed. This is in line with 
literature that suggests that the propargylamine moiety is a good contributor to MAO 
inhibitory capacity (Bar-Am et al., 2005). 
The compounds that had the carbamate moiety had better activity that their urea linked 
counterparts. We observe this when we compare 1B with 3B and 2B with 4B. We can 
go on to surmise that the electron accepting abilities of the oxygen molecule contributes 
to some interaction in the MAO-B active site. Compounds 2B and 4B had the lowest 
IC50 values of 2.62 and 1.84 µM respectively. It is noted that these compounds had the 
carbamate moiety at position 6 and the position 1 propargylamine moiety similar to 
ladostigil. Our deduction is that this orientation of the propargylamine to the carbamoyl 
moiety is favours good inhibitory activity of the compounds.  
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Figure 4.11: Non-linear regression curves for MAO-B activity for the tested 
compounds and rasagiline as control. IC50 values are shown (p < 0.05) 
Comparison of the four most active compounds to rasagiline (IC50 = 0.58 µM) 
demonstrates that our compounds 2B and 4B are good inhibitors of MAO-B. Earlier we 
hypothesised that the indole polycyclic ring contributes to MAO inhibitory capacity and 
it is in this case that its abilities can be highlighted. Also, these compounds are 
considerably longer in length compared to rasagiline and could possibly fit better into 
the elongated active site with better orientation and interactions. 
Table 4.3:IC50 and selectivity indices of the compounds towards MAO 
Compound ID MAO-A MAO-B SI {
     
     
} 
1A >100 >100 -- 
2A 20,37 >100 -- 
3A 13,15 >100 -- 
4A 88,11 >100 -- 
1B 33,42 28,84 1.16 
2B 4,31 2,62 1.64 
3B 99,08 16,52 6 
4B 51,64 1,84 28.11 
3A 
2B 1B 
2A 1A 
4A 
3B 4B RAS 
IC50 = > 100 µM IC50 = > 100 µM 
IC50 = > 100 µM 
IC50 = > 100 µM IC50 = 91.20 µM IC50 = 2.62 µM 
IC50 = 16.52 µM 
IC50 = 1.84 µM IC50 = 0.58 µM 
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As can be seen from the table above compounds 1A, 2A, 3A and 4A which inhibit the 
MAO-A isozyme at lower concentrations compared to MAO-B inhibition may prove 
selective for it and so may contribute to peripheral potentiation of tyramine levels (a 
consequence of high peripheral MAO-A inhibition). However if the compounds prove 
to be reversible inhibitors then this shortcoming becomes inconsequential as tyramine 
cannot cross the blood brain barrier (Haefely et al., 1992). If a compound is reversible 
in its inhibition of the MAO-A enzyme tyramine will eventually be metabolised 
peripherally and will not accumulate as happens in the case of non-reversibility 
(Youdim and Weinstock, 2004).The rest of the compounds are close to non-selective 
inhibitors of the enzyme with very low SI values. This means that the compounds 
would inhibit both enzymes in equal capacity except perhaps compound 4Bthat may 
prove more selective for MAO-B. 
4.5 IN VITRO INHIBITORY DATA OF LADOSTIGIL AND 2B 
The design objectives and strategy of this study were based on the MTDL paradigm of 
drug discovery as well as the dual ChE-MAO inhibitor ladostigil currently in clinical 
trials (Avraham Pharma, 2016). Hence before concluding this chapter it is necessary to 
compare the results of the compounds in this study to the ChE and MAO inhibitory 
activity of ladostigil. 
Compound 2B showed the best overall activity with good IC50 values for all the tested 
enzymes. As a result we compared ladostigil to compound 2B (Graph 4.1). The ChE 
and MAO studies for ladostigil were carried out under similar assay conditions and the 
same enzyme species as those used in this study (Sterling et al., 2002). 
As can be seen from Graph 5.12 compound 2B had almost 9-fold increase in activity on 
AChE. We ascribe this to the indole ring that we used as compared to the indane moeity 
that ladostigil and rasagiline possess. Notably compound 2B possesses a urea compared 
to the carbamate on ladostigil, which may portray superior interactions The two 
compounds are more or less equipotent BuChE inhibitors indicating that compound 
2Bcould actively prevent BuChE induced hydrolysis of acetylcholine. 
 
                                                          
2 NT: Not tested, ladostigil was not tested in vitro for MAO inhibitory activity. 
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MAO-B enzyme compared to ladostigil. This, together with the AChE abilities of the 
compound would mean a reduction in consumed concentrations, reduce
and a more effective treatment option. Moreover we may attribute the good activity of 
the compound 2B towards MAO being due to the presence of the indole polycyclic ring 
compared to the indane of ladostigil. 
The propargylamine is conjugated
the chiral centre present in ladostigil and (2) the secondary amine versus a tertiary 
amine with possibly better interactions with the enzyme.
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4.6 STABILITY TESTING 
Chemical stability of pharmaceutical molecules is a matter of great importance as it 
ultimately affects the stability and efficacy of the final drug product. One of the 
drawbacks of the carbamate linkage of ladostigil is its ability to be rapidly hydrolysed 
in acidic conditions. Considering that the compounds in our study contained a 
carbamate or urea linkage that may affect stability, we decided to employ a forced 
chemical degradation test to study the stability of these moieties. 
4.6.1 METHODS 
Blessy et al., 2014, recommended a range of conditions mostly used for forced 
degradation studies and we modified our method accordingly. Compounds 2B and 4B 
were selected for the testing because they contained both the carbamoyl and 
propargylamine moiety and portrayed good activity as either a carbamate (2B) or urea 
(4B) derivative. Test compound (1 mg) was dissolved per ml water with DMF as co-
solvent. Hydrochloric acid (HCl, 0.1 M) or 0.1 M NaOH were used to adjust the pH of 
the solutions with water as control. The solutions were kept at 37ºC in an incubator for 
7 days and sampled on days 0, 1, 3, 4 and 7. UV/vis absorbance of the sample was 
measured at maximal wavelengths of 232 nm for 2B and 234 nm for 4B. 
4.6.2 RESULTS AND DISCUSSION 
It is important to note that both urea and carbamate functional groups undergo 
hydrolysis but at different rates. Amides undergo hydrolysis at a slower rate than the 
structurally related esters under comparable reaction conditions(Armstrong, Farlow and 
Moodie, 1968).Hence our aim in this study was to produce compounds that are more 
stable in acidic and basic conditions. Graph 4.2 shows the results of the compounds 
after 7 days in 0.1 M HCl. 
Compound 2Bdisplayed an almost linear reduction in intact compound compared to 
4Bthat portrayed a more rapid decay. From these result we can postulate that the 
carbamates are less stable than their urea containing counterparts. Ladostigil is a 
carbamate linked compound and so could act similarly to 4Bin acid conditions. 
Following this logic, urea linked 2B should prove to be more stable than the carbamate 
derivative ladostigil. This should minimise the metabolic effects that induce rapid 
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hydrolysis to prevent limiting factors such as a short half life. The compounds behaved 
in a similar manner in alkaline conditions (Graph 4.3). 
0.1 M HCl Acid
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We can see that 4B acts poorly in both conditions resulting in a situation where the 
whole molecule is degraded or broken down at a rapid rate as compared to 2B. At this 
stage we are not informed as to the activity of the metabolites of the compounds but like 
rasagiline and ladostigil whose metabolites portray neuroprotective activity; our 
compounds may act in a similar manner. 
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4.7 CONCLUSION 
The main objective of this study was to design a series of chemically stable novel 
multifunctional compounds able to inhibit AChE, BuChE, MAO-A and MAO-B. We 
Graph 4.2: Chemical stability in 0.1 M HCl 
Graph 4.3: Chemic l stability in 0.1 M NaOH 
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managed to synthesise 8 compounds with the desired pharmacophoric groups. The 
assay results are summarised in the Table 4.4. 
Table 4.4: Summary of the IC50 values of all novel compounds 
Compound ID AChE (µM) BuChE (µM) MAO-A (µM) MAO-B (µM) 
1A 1,97 3,48 >100 >100 
2A 2,28 4,55 20,37 >100 
3A 2,78 2,29 13,15 >100 
4A 3,72 3,18 88,11 >100 
1B 2,77 3,96 33,42 28,84 
2B 3,70 2,82 4,31 2,62 
3B 2,57 3,01 99,08 16,52 
4B 2,41 5,01 51,64 1,84 
These results indicate that the compounds could act as dual non-selective cholinesterase 
inhibitors to inhibit the hydrolysis of acetylcholine and hence increase its levels post-
synapse. The cholinesterase assays have given us a proof of concept regarding the 
ability of the carbamoyl moiety to inhibit the cholinesterase class of enzymes. We have 
identified the urea moiety as an improvement to the carbamoyl portion especially in the 
propargylated compounds. Addition of the propargylamine group did not influence ChE 
activity. The compounds have been shown to be more potent than the FDA approved 
AChE inhibitor rivastigmine (U.S. Food and Drug Administration).  
Addition of the propargylamine moiety yielded compounds that were active towards the 
MAO enzymes. Again here we have proof of concept of the moiety’s inhibitory 
properties. Comparison with rasagiline or ladostigil proves that some of our compounds 
may serve as lead compounds for optimisation. Compound 2B was particularly (on 
average) a good inhibitor of all 4 enzymes (IC50 AChE = 3.70 µM, BuChE = 2.82µM, 
MAO-A = 4.31 µM and MAO-B = 2.62 µM). The results of the chemical stability tests 
showed that it (2B) is also more stable than the carbamate linked compound 4B by 
virtue of possessing the urea. We also managed to eliminate the stereochemistry 
associated with ladostigil and rasagiline. Compound 2B would thus probably prove 
more chemically stable than ladostigil. This compound can thus be considered for 
optimisation and perhaps development as a multipotent drug molecule against 
Alzheimer’s disease. 
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CHAPTER 5 
5. CONCLUSION 
5.1 INTRODUCTION 
Our understanding of AD has advanced enormously over the past few years, with much 
effort being devoted into research ligands that portray excellent in vivo activity. 
However these highly selective ligands do not necessarily result into clinically effective 
drugs due to the multifactorial nature of the disease (Cavalli et al., 2008). In response, 
different pharmacological approaches, such as polypharmacy, have offered possible 
means of overcoming the drawbacks of single target therapies. Recent research has 
introduced the concept of MTDLs which is simply a molecule that can target multiple 
pathways that contribute to disease pathogenesis (Bolognesi et al., 2006, Zhang, 2005). 
We capitalised on the structural relevance of single target molecules to design a series 
of compounds where pharmacophoric moieties of rivastigmine and rasagiline were 
employed to obtain compounds proposed to inhibit both cholinesterase and MAO 
enzymes respectively. We further incorporated an indole polycyclic nucleus for which 
anti-oxidant and NOS inhibitory capacity has been reported (Buemi et al., 
2013,Fernández García, et al., 1992). 
5.2 SYNTHESIS 
In order to obtain the desired series of compounds, SN2 nucleophilic substitution 
reactions were employed to conjugate the carbamoyl and propargyl moieties to the 
indole polycyclic ring. The first series of compounds had the carbamoyl moiety at either 
the 5 or 6 position of the indole polycyclic ring. Of the 4 synthesised compounds 2 
possessed the carbamate bond and 2 the urea. The synthesis of these compounds 1A, 
2A, 3A and 4A (Table 5.1) was carried out under conventional conditions (room 
temperature and stirring for 2 hours). The yields ranged from 50 to 80 %.These 
compounds were then used to further synthesise a series of 4 propargylated compounds 
1B, 2B, 3B and 4B. The propargylamine moiety was conjugated to the N1 position to 
yield final compounds similar to ladostigil. These reactions were carried out in the 
microwave to provide sufficient energy for the propargylamine moiety to react. The 
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final products were obtained in yields of over 75 %.NMR and IR spectra showed 
characteristic signals and MS confirmed the compounds. 
Within the series, the compounds were differentiated by the type of linkage of the 
carbamoyl moiety (carbamate or urea) and the position of this conjugation (5 or 6). A 
total of 8 compounds were successfully synthesised and characterised as shown in 
Table 5.1. 
Table 5.1: Successfully synthesised series of compounds. 
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NH
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N
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O
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4B 
NO
O
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5.3 MOLECULAR MODELLING AND BIOLOGICAL 
EVALUATION 
Docking studies of the novel compounds on the AChE, MAO–A and MAO–B enzymes 
were performed to elucidate possible binding interactions in the active sites. The AChE 
modelling results showed that the compounds possessed vital interactions with the 
cholinesterase active site. Both series of compounds showed interaction with Trp84, a 
key residue in the CAS. The propargylamine moieties of the structures were oriented 
towards the FAD cofactor of the MAO isozymes and hence should have good inhibitory 
activity. Some interactions were also observed between the indole ring with Trp 279 in 
AChE and Ille 199 in MAO which showed that it plays a role in the inhibitory capacity 
of the compounds. 
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The in vitro biological testing of all the synthesised compounds for cholinesterase and 
MAO inhibitory activity was carried out using electrophorus electricus AChE, equine 
BuChE and recombinant human forms of the MAO–A and -B enzymes. The assay 
results showed that the compounds are dual and non-selective inhibitors of the 
cholinesterase enzymes in vitro. They all possessed IC50 values lower than 5 µM. 
Addition of the propargylamine substitution on position 1 did not influence ChE 
inhibitory activity significantly.  
 
The compounds possessed good activity towards MAO – A and B and the presence of 
the urea moiety resulted in compounds that have comparably better inhibitory capacities 
than the carbamate linked compounds. Some of the compounds (2A and 3A) showed 
uncharacteristically good activity on the MAO–A enzyme compared to their 
propargylated counterparts. The compounds that had the propargylamine moiety had 
good inhibitory activity except 3B with 2Band 4B portraying the lowest IC50 values. 
The compounds were overall more selective towards MAO – B. 
0
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Compound 2B portrayed the best overall activity of all the tested compounds. When 
compared to ladostigil, compound 2B demonstrated an AChE inhibitory capacity 9 
times that of ladostigil and a 13 fold increase in MAO–B inhibition. The two are more 
or less equipotent BuChE inhibitors. Moreover compound 2B also possesses superior 
MAO–A inhibitory capacity in vitro. Compound2B is also more chemically stable 
compared to the carbamate linked compound 4B based on a 7 day forced degradation 
study. These results indicate that the compound may prove more stable than ladostigil. 
This compound can thus be considered for optimisation and perhaps development as a 
multipotent drug molecule against Alzheimer’s disease. 
5.4 CONCLUSION 
Research in the area of AD has been ongoing for many years and has not resulted in a 
set treatment option for the disease. Current therapies, rivastigmine and memantine 
affect the symptomatic stages to provide palliative care. Over the last 2 decades 
research trends have shifted from the one drug–one target paradigm to multifunctional 
molecules. In this light, numerous targets have been explored to achieve an ultimate 
multi–potent molecule against the ChE and MAO enzymes, apoptosis as well as 
amyloid plaque formation. 
The objective of this study was to synthesise and evaluate a series of compounds with 
the indole ring, propargylamine and carbamate/urea moieties to inhibit AChE, BuChE 
and MAO. Eight novel compounds were successfully synthesised and evaluated and 
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they all proved to be good inhibitors of the cholinesterase enzymes. They also proved to 
inhibit MAO enzymes especially with the propargylamine moiety added. This proves 
that the novel compounds have great potential in alleviating the cholinergic symptoms 
of AD, reducing the rate of amyloid plaque formation in the brain, confer 
neuroprotection by inhibiting the MAO catalysed breakdown of amine 
neurotransmitters and in total reduce the progression of AD. 
With regards to future studies, the anti–apoptotic potential and ability of the compounds 
to cross the blood brain barrier is the next step to ascertain the full capacity of the 
compounds to affect a significant change in all stages of Alzheimer’s disease.  
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Spectrum 1: HNMR COMPOUND 1A 
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Spectrum 2: 13C NMR COMPOUND 1A 
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Spectrum 3: IR COMPOUND 1A  
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Spectrum 4: MS COMPOUND 1A 
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Spectrum 5: HNMR COMPOUND  2A 
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Spectrum 6: 13C NMR COMPOUND 2A 
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Spectrum 7: IR COMPOUND 2A  
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Spectrum 8: MS COMPOUND 2A 
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Spectrum 9: HNMR COMPOUND 3A 
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Spectrum 10: 13C NMR COMPOUND 3A 
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Spectrum 11: IR COMPOUND 3A 
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Spectrum 12: MS COMPOUND 3A 
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Spectrum 13: HNMR COMPOUND 4A  
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Spectrum 14: 13C NMR COMPOUND 4A 
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Spectrum 15: IR COMPOUND 4A 
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Spectrum 16: MS COMPOUND 4A 
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Spectrum 17: HNMR COMPOUND 1B  
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Spectrum 18: 13C NMR COMPOUND 1B 
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Spectrum 19: IR COMPOUND 1B  
 
 
4000.0 3600 3200 2800 2400 2000 1800 1600 1400 1200 1000 800 650.0
52.5
54
56
58
60
62
64
66
68
70
72
74
76
78
80
82
84
86
88
90
92
94
96
97.8
cm-1
%T 
3293.69
2922.34
2853.87
1761.13
1634.77
1536.56
1408.22
1344.84
1217.23
1081.31
854.74
798.45
756.64
720.43
N
NH
O
N
http://etd.uwc.ac.za/
  
 
 
 
Spectrum 20: MS COMPOUND 1B 
113 
 
http://etd.uwc.ac.za/
  
 
 
 
114 
Spectrum 21: HNMR COMPOUND 2B  
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Spectrum 22: 13C NMR COMPOUND 2B 
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Spectrum 23: IR COMPOUND 2B  
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Spectrum 24: MS COMPOUND 2B 
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Spectrum 25: HNMR COMPOUND 3B 
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Spectrum 26: 13C NMR COMPOUND 3B 
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Spectrum 27: IR COMPOUND 3B  
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Spectrum 28: MS COMPOUND 3B 
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Spectrum 29: HNMR COMPOUND 4B  
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Spectrum 26: 13C NMR COMPOUND 4B 
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Spectrum 31: IR COMPOUND 4B  
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Spectrum 32: MS COMPOUND 4B 
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